anticancer research article processing charge

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts

Publishing options

Authors submitting primary research articles to Nature Cancer have the option of publishing their research using either:

1 – Traditional subscription publishing model  – an article is submitted and is assessed by our editors. If suitable it will be put through Peer Review, and if successful (subject to amendments), will be eligible for publication. Published articles are made available to institutions and individuals who subscribe to Nature Cancer or who pay to read specific articles.

2 – Gold Open Access  – same publishing process as above. The difference is that when an article is accepted for publication, the author/s or funder/s pay an Article Processing Charge (APC). The final version of the published article is then free to read for everyone. The   APC to publish Gold Open Access in Nature Cancer is £8890.00/$12290.00/€10290.00. 

Find out more about Open Access .

Articles that are published OA are freely available online, and are published under a  Creative Commons CC-BY license , which allows for reuse and sharing. The publishing costs are covered by the author’s institution or funding body paying an Article Processing Charge (APC).

OPEN ACCESS FUNDING

For information about research funders and institutions that provide funding for APCs, visit Springer Nature’s  open access funding & support services .

Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our  open access agreements  to check your eligibility.

THE BENEFITS OF PUBLISHING OPEN ACCESS

• For authors  – their work is seen by more people. Open Access articles are viewed and cited more often than articles behind a paywall.
• For readers  – they can access and build upon the most recent work in their field. Content is available, and reusable for all.
• For funders  – the work they fund will reach a wider audience and will have a more immediate impact.

Find out more about the benefits of Open Access publishing .

If authors need to publish OA because they are mandated to by their institution or funder, they can choose this route. For those who do not have these restrictions, they can choose to publish either via the subscription route or OA. The corresponding author will need to select which publishing option they want after their research is accepted.

Authors may need to take specific actions to achieve compliance with funder and institutional open access mandates. If your research is supported by a funder that requires immediate open access (e.g. according to Plan S principles ) then you should select the gold OA route, and we will direct you to the compliant route where possible. For authors selecting the subscription publication route, the journal's standard licensing terms will need to be accepted, including self-archiving policies . Those licensing terms will supersede any other terms that the author or any third party may assert apply to any version of the manuscript.

The selection of the publishing model will happen after the paper has undergone editorial processing and been accepted. All papers, regardless of the publishing model, submitted to Nature Cancer will continue to receive high levels of personal author service, editorial rigour, peer-review, and high quality publishing services from our team of in-house editors.

WHAT IS AN ARTICLE PROCESSING CHARGE?

The Article Processing Charge (APC) is the amount authors are charged when their manuscript is accepted for publication. APCs cover the following:

• Editorial work:  assess and select the most important research to publish, partner with authors and reviewers to deliver significant improvements to manuscripts through our rigorous and intensive review process, manage peer review, bespoke correspondence with authors, administrative support and journal development.
• Technical infrastructure and innovation:  development, maintenance and operation of online journal systems and websites.
• Production of articles:  formatting, lay-out and mark-up of articles, copy editing and inclusion in indexing services.
• Promotion of journal and content:  making sure readers and authors know about the work published in the journal.
• Customer service:  responding to the needs of authors and readers.

Find out more about how we select, edit, publish, curate and promote scientific research.

Nature Cancer aims to provide the highest levels of author service, editorial rigour and consistency. Our in-house team of highly qualified, professional, independent editors:

• read and evaluate all submissions
• decide which papers to send out to peer review
• guide authors and reviewers through the peer review process
• decide which papers to accept
• work with authors to ensure the highest standards of research reporting and sharing are followed.

All our editors come from academic environments, are all PhD-level, and have a deep understanding of scientific research and publishing.

GOLD OA FUND A dedicated fund is available to enable authors from countries currently classified by the World Bank as low-income (LIC) or lower-middle-income economies (LMICs) to publish their primary research OA in Nature and the Nature research journals. For more information, please visit our policy pages .

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Advertisement

Publication Fees and Reprints

To defray publication costs and to support other AACR programs, the corresponding author of an accepted manuscript will be invoiced based on the journal’s publication fees as detailed herein. Authors are required to confirm at the time of submission that they agree to pay the article publication fees in the event that their manuscript is accepted for publication. Please note that, with the exception of articles published under an open access license in the AACR hybrid journals, only manuscripts from 25+ countries are subject to the full price. All other manuscripts will receive a country-specific discount based on the location of the primary affiliation of the corresponding author; see Publication Fee Discounts below for details of this and other discounts.

Standard AACR Publication Fees

For articles published under a copyright transfer agreement, the AACR journals charge a fixed base publication fee determined by the journal, as well as a standard handling fee for each display item (figure or table) as detailed in the table below.

Open Access Fees

Authors who wish to publish under an open access license may do so by paying a single flat article processing charge (APC) as noted in the table below. The amount of the APC is determined based on the journal and the type of open access license. The Creative Commons license options for open access publication are as follows:

• CC BY-NC-ND—This license permits free access and redistribution and noncommercial use with proper attribution.
• CC BY—This license permits free access, redistribution, commercial use, and derivative works with proper attribution.

• Cancer Discovery
• Publication Fees (Copyright Transfer only)
• Base Publication Fee * : $5000 #
• Display Item Fee * : $250 per item
• APCs (Open Access only)
• CC BY-NC-ND: $10000
• CC BY: $11000
• Blood Cancer Discovery
• Base Publication Fee * : $2500 #, **
• CC BY-NC-ND: $7000
• CC BY: $8000
• Cancer Research
• Base Publication Fee * : $2700 #
• Clinical Cancer Research
• Cancer Immunology Research
• Molecular Cancer Research
• Base Publication Fee * : $1900
• CC BY-NC-ND: $6000
• CC BY: $7000
• Molecular Cancer Therapeutics
• Cancer Epidemiology, Biomarkers & Prevention
• Base Publication Fee * : $600 #
• CC BY-NC-ND: $4000
• CC BY: $5000
• Cancer Prevention Research
• Cancer Research Communications
• Base Publication Fee * : NA
• Display Item Fee * :NA
• CC BY-NC-ND: NA
• CC BY: $2550 **,***

Certain invited article types solicited directly by an editor will be published under standard copyright transfer and the associated publication fees waived. If an invited author requests open access publication, the APC will not be waived. APCs may be discounted for commentary-style content at the AACR’s discretion.

Publication Fee Discounts

The AACR provides authors with a variety of discounts to the standard publication fees, which allows them to reduce, and in some cases eliminate, the cost of publication. Most discounts are automatically applied on behalf of the author. Descriptions of these discounts, and who qualifies for them, are described below.

AACR Membership Discount

If the corresponding, first, or last author is in the Active AACR membership Category , a 10% discount on the total charges, excluding any open access fee, is applied. In order to obtain the discount, the corresponding author should ensure that the full membership information for the relevant member is entered into the manuscript submission system, SmartSubmit.

If the manuscript has a qualifying AACR member author who is in the Population Sciences , Cancer Immunology , or Cancer Prevention AACR Working Group, and the manuscript does not qualify for the AACR Editor Discount below, an additional 5% discount will be applied to manuscripts accepted at Cancer Epidemiology, Biomarkers & Prevention , Cancer Immunology Research , or Cancer Prevention Research respectively. To obtain the increased discount, the author must supply the journal with the appropriate discount code. The necessary code may be found on the working group webpages.

AACR Editor Discount

A manuscript with a qualifying Editor from an AACR journal listed as an author will receive a discount of 25% on the total charges, excluding any open access fee. Such manuscripts are also eligible for the AACR member discount detailed above.

AACR Grantee Discount

A manuscript describing work supported by an AACR grant will receive a discount of 25% on the total charges, excluding any open access fee. Such manuscripts are also eligible for the AACR member discount detailed above.

Country-Specific Discounts

The AACR understands that researchers in many countries have considerably fewer resources than others to support the payment of publication costs. To address these financial realities, the AACR journals provide three levels of pricing discount (25%, 50% or 100%) based on the location of the primary affiliation of the corresponding author listed in the author byline of the accepted manuscript. These country-specific discounts will not be provided to support publication of manuscripts describing work principally conducted for a commercial organization. This discount is applied to the total charges, excluding any open access fee; but it is applied to the APC at Cancer Research Communications as described below. An author receiving this discount may also benefit from the AACR membership discount detailed above. The lists below delineate the countries for which country-specific discounts are or are not provided. If a country is not listed, it may be assumed to fall in the 100% discount category. Country classification is based on R&D funding per capita and cancer funding measured by total active grant-based funding and average grant size. Classifications are subject to change early each year.

Full Price Australia, Austria, Belgium, Canada, China, Czechia, Denmark, Estonia, Finland, France, Germany, Hong Kong SAR (China), Iceland, Ireland, Israel, Italy, Japan, Luxembourg, Netherlands, New Zealand, Norway, Poland, Portugal, Qatar, Republic of Korea, Singapore, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Arab Emirates, United Kingdom, United States

25% Discount Croatia, Cyprus, Greece, Hungary, Lithuania, Macao SAR (China), Malta, Slovakia

50% Discount Andorra, Bahrain, Brunei Darussalam, Bulgaria, Gibraltar, Greenland, Isle of Man, Latvia, Liechtenstein, Malaysia, Monaco, Puerto Rico, San Marino, Saudi Arabia, Serbia, Thailand

100% Discount Afghanistan, Aland Islands, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, Antigua and Barbuda, Argentina, Armenia, Aruba, Azerbaijan, Bahamas, Bangladesh, Barbados, Belarus, Belize, Benin, Bermuda, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Bouvet Island, Brazil, British Indian Ocean Territory, British Virgin Islands, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Cayman Islands, Central African Republic, Chad, Chile, Christmas Island, Cocos (Keeling) Islands, Colombia, Comoros, Congo (Brazzaville), Congo (Kinshasa), Cook Islands, Costa Rica, Côte d'Ivoire, Cuba, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Falkland Islands (Malvinas), Faroe Islands, Fiji, French Guiana, French Polynesia, French Southern Territories, Gabon, Gambia, Georgia, Ghana, Grenada, Guadeloupe, Guam, Guatemala, Guernsey, Guinea, Guinea-Bissau, Guyana, Haiti, Heard and Mcdonald Islands, Holy See (Vatican City State), Honduras, India, Indonesia, Iran, Iraq, Jamaica, Jersey, Jordan, Kazakhstan, Kenya, Kiribati, Korea (North), Kuwait, Kyrgyzstan, Lao PDR, Lebanon, Lesotho, Liberia, Libya, Macedonia, Madagascar, Malawi, Maldives, Mali, Marshall Islands, Martinique, Mauritania, Mauritius, Mayotte, Mexico, Micronesia, Moldova, Mongolia, Montenegro, Montserrat, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Netherlands Antilles, New Caledonia, Nicaragua, Niger, Nigeria, Niue , Norfolk Island, Northern Mariana Islands, Oman, Pakistan, Palau, Palestinian Territory, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Pitcairn, Réunion, Romania, Russian Federation, Rwanda, Saint Helena, Saint Kitts and Nevis, Saint Lucia, Saint Pierre and Miquelon, Saint Vincent and Grenadines, Saint-Barthélemy, Saint-Martin (French part), Samoa, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Solomon Islands, Somalia, South Africa, South Georgia and the South Sandwich Islands, South Sudan, Sri Lanka, Sudan, Suriname, Svalbard and Jan Mayen Islands, Swaziland, Syrian Arab Republic (Syria), Tajikistan, Tanzania, Timor-Leste, Togo, Tokelau, Tonga, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Turks and Caicos Islands, Tuvalu, Uganda, Ukraine, Uruguay, US Minor Outlying Islands, Uzbekistan, Vanuatu, Venezuela (Bolivarian Republic), Viet Nam, Virgin Islands (US), Wallis and Futuna Islands, Western Sahara, Yemen, Zambia, Zimbabwe

Under exceptional circumstances, authors who would not qualify for a country-specific discount, or who would qualify for the lower 25% or 50% discount, may apply to the Publisher at the time of submission for an additional discount on the standard publication fees. All such applications must be countersigned by an appropriate institutional official stating that insufficient funds are available for the payment of the publication fees.

Manuscript Turnaround Guarantee Discount

The AACR journals work very hard to provide fast and fair decisions after peer review. In the unlikely event that their peer review does not meet a minimum standard of timeliness, authors may take advantage of our Manuscript Turnaround Guarantee and receive a full refund of the total charges, excluding any open access fee.

Cancer Research Communications Fees

Cancer Research Communications is an online-only, exclusively open access journal. As such, unlike the other AACR journals noted above it has a flat article publication charge (APC). During the current launch phase, Cancer Research Communications has a special introductory APC of $2,550.

If the corresponding, first, or last author is in the Active AACR membership category , the APC is $2,200. To obtain the discount, the corresponding author must ensure that the full membership information for the relevant member is entered into the manuscript submission system, SmartSubmit.

If the manuscript has a qualifying Editor from an AACR journal listed as an author, the APC is $1,500.

Cancer Research Communications manuscripts are eligible for the country-specific discounts described above. No other discounts are available.

Any article processing charges (publication, display item, and open access fees) are being processed through RightsLink ® , an online billing platform tailored for the AACR by the Copyright Clearance Center. If a manuscript is accepted and there are article processing charges associated with the manuscript, RightsLink ® provides authors with a simple way to manage and pay charges online via an email prompt shortly after acceptance.

Authors have the opportunity to order up to 100 reprints of their articles when they receive their article proofs for approval prior to publication. A link will be provided to the Sheridan Electronic Order Center where reprint fees are detailed and payment can be made. Authors who have questions about fees should contact the AACR Publications Department at [email protected] .

Anyone who would like to purchase bulk reprints of an article but who is not a listed author can find information about this at Third Party Permission and Reprints .

Information for Authors  »

Select a journal  », editorial process  », editorial policies  », article style and formats  », copyright transfer and article reuse  », open access, free access, and article archiving  », standard aacr journal fees, faq  », aacr journals.

• Info for Advertisers
• Information for Institutions/Librarians

• Privacy Policy
• Copyright © 2023 by the American Association for Cancer Research.

This Feature Is Available To Subscribers Only

Sign In or Create an Account

Fees and funding

Article processing charges (apc).

Authors who publish open access in Journal of Experimental & Clinical Cancer Research are required to pay an article processing charge (APC). The APC price will be determined from the date on which the article is accepted for publication.

The current APC, subject to VAT or local taxes where applicable, is: £2890.00/$3990.00/€3390.00

Visit our open access support portal and our Journal Pricing FAQs for further information.

Open access funding

Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.

Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.

Springer Nature offers APC waivers and discounts for articles published in our fully open access journals whose corresponding authors are based in the world’s lowest income countries (see our APC waivers and discounts policy for further information). Requests for APC waivers and discounts from other authors will be considered on a case-by-case basis, and may be granted in cases of financial need (see our open access policies for journals for more information). All applications for discretionary APC waivers and discounts should be made at the point of manuscript submission; requests made during the review process or after acceptance are unable to be considered.

Owned by the  Association for International Promotion & Study in Tumors (APSIT)

Official journal of the  Regina Elena National Cancer Institute , Scientific Director Gennaro Ciliberto, Rome, Italy

• Editorial Board
• Manuscript editing services
• Instructions for Editors
• Sign up for article alerts and news from this journal
• Submit manuscript

Annual Journal Metrics

2022 Citation Impact 11.3 - 2-year Impact Factor 11.5 - 5-year Impact Factor 1.870 - SNIP (Source Normalized Impact per Paper) 2.413 - SJR (SCImago Journal Rank)

2023 Speed 4 days submission to first editorial decision for all manuscripts (Median) 100 days submission to accept (Median)

2023 Usage  3,003,080 downloads 3,022 Altmetric mentions

• More about our metrics

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

• Submission enquiries: Access here and click Contact Us
• General enquiries: [email protected]

Anti-Cancer Agents in Medicinal Chemistry

(Formerly as Current Medicinal Chemistry - Anti-Cancer Agents )

Impact Factor : 2.8

Indexed in: Scopus, SCI Expanded, MEDLINE/PubMed... View all

Volume 24 , Issues 20, 2024

This journal supports open access

Submission for General Articles

Submit to thematic issues, author guidelines ☰ toggle sidepanel -->.

Authors are requested to electronically submit their papers to this journal for evaluation and submission at https://bentham.manuscriptpoint.com/journals/acamc / View Submission Instructions . The Manuscript Processing System (MPS) has been designed to ensure step-by-step online processing and tracking of manuscripts for authors, editors and the publisher from submission to acceptance and final reproduction.

Through the submission process, this website will guide authors through each stage of the submission process. The text, tables, and artwork should be uploaded at ( https://bentham.manuscriptpoint.com/journals/acamc ) in electronic format by the authors. However, the authors who are unable to provide an electronic version or who are facing other difficulties must contact the editorial office by emailing at [email protected] to discuss any alternatives. Submissions that do not adhere to these guidelines will unfortunately not be taken into consideration.

Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The principal/corresponding author will be required to submit a Copyright Letter along with the manuscript, on behalf of all the co-authors (if any). The author(s) will confirm that the manuscript (or any part of it) has not been published previously or is not under consideration for publication elsewhere. Furthermore, any illustration, structure, or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained.

The author's time is valuable and should not be wasted on research formatting. Free Format Submission makes it easier and faster to prepare text for submission.

When submitting to any Bentham journal, authors are not required to follow any formatting guidelines. When an article is accepted for publication, authors can submit it in the format of their choice, and Bentham will convert it into a journal-specific format for them.

If the submission is accepted for publication, Bentham will format it in accordance with the style and format of the journal.

For all online submissions, please provide soft copies ofall the materials (main text in MS Word or Tex/LaTeX), figures/illustrations in TIFF, PDF or JPEG, and chemical structures drawn in ChemDraw (CDX)/ISISDraw (TGF) as separate files, while a PDF version of the entire manuscript must also be included, embedded with all the figures/illustrations/tables /chemical, structures, etc ., It is advisable that the document files related to a manuscript submission should always have the name of the corresponding author as part of the file name, i.e., "Cilli MS text.doc," "Cilli MS Figure 1", etc .

It is imperative that before submission, authors should carefully proofread the files for special characters, mathematical symbols, Greek letters, equations, tables, references and images, to ensure that they appear in a proper format.

References, figures, tables, chemical, structures, etc ., should be referred to in the text at the appropriate place where they have been first discussed. Figure legends/captions should also be provided.

Successful electronic submission of a manuscript will be followed by a system-generated acknowledgements to the principal/corresponding author. Any queries therein should be addressed to [email protected]

Authors who publish in Bentham Science print & online journals will transfer copyright to their work to Bentham Science Publishers. Submission of a manuscript to the respective journals implies that all authors have read and agreed to the content of the Copyright Letter or the Terms and Conditions. It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication. Once submitted to the journal, the author will not withdraw their manuscript at any stage prior to publication.

It is mandatory that a signed copyright letter also be submitted along with the manuscript by the author to whom correspondence is to be addressed. The article should not contain any such material or information that may be unlawful, defamatory, fabricated, plagiarized, or which would, if published, in any way whatsoever, violate the terms and conditions as laid down in the copyright agreement. Copyright letter can be downloaded from the journal's Web site. Download the Copyright letter.

Permission to Reuse Bentham Content

Bentham Science has collaborated with the Copyright Clearance Center to meet our customer’s licensing, besides rights & permission needs.

The Copyright Clearance Center’s RightsLink® service makes it faster and easier to secure permission from Bentham Science’s journal titles. Visit Journals by Title and locate the desired content. Then go to the article’s abstract and click on “Rights and Permissions” to open the RightsLink’s page. If authors can't find the content they are looking for or can't get the rights they need, please contact us at [email protected]

Third-Party Permissions

Authors are responsible for managing the inclusion of third-party content as an author/editor of a work. We refer to 'third party content' as any work that authors haven't developed themselves and have copied or adapted from other sources. Text, figures, photographs, tables, screenshots, and other items may be included.

Unless the figure is in the public domain (copyright-free) or permitted for use under Creative Commons or other open licences, the author must get permission from the copyright holder(s).

Published/reproduced material should not be included unless written permission has been obtained from the copyright holder, which should be forwarded to the Editorial Office in case of acceptance of the article for publication.

Articles are licensed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0) ( https://creativecommons.org/licenses/by/4.0/legalcode ), which permits unrestricted distribution and reproduction in any medium, as long as the work is properly credited/attributed. For more details, please visit Open Access Policy

By signing the Copyright Letter, the authors retain the rights of self-archiving (subject to certain restrictions).

Following are the important features of the self-archiving policy of Bentham Science journals:

Authors can deposit the first draft of a submitted article on their personal websites or their institution's repositories for personal use, internal institutional use, or for permitted scholarly posting only.

Authors may deposit the ACCEPTED VERSION of the peer-reviewed article on their personal websites, their institution's repository or the non-commercial repositories, PMC and arXiv, after 12 MONTHS of publication on the journal website. For personal use, internal institutional use, or for permitted scholarly posting only.

In case of (b) above, an acknowledgement must be given to the original source of publication and a link must be inserted to the published article on the journal's/publisher's website. The link to the original source of publication should be provided by inserting the DOI number of the article in the following sentence: "The published manuscript is available at EurekaSelect https://www.eurekaselect.com/openurl/content.php?genre=article&doi= ."

If the research is funded by NIH, Wellcome Trust or any other Open Access Mandate, authors are allowed the archiving of published versions of manuscripts in the nominated institutional repositories, after the mandatory embargo period. Authors should first contact the Editorial Office of the journal for information about depositing a copy of the manuscript to a repository. Consistent with the copyright agreement, Bentham Science does not allow archiving of FINAL PUBLISHED VERSION of manuscripts unless under an Open Access mandate as above. Archiving, under any of the above mentioned Open Access mandates, is done under the terms of the Creative Commons License CC BY-NC-ND 4.0 - Attribution-NonCommercial-NoDerivatives 4.0 International .

There is no embargo on the archiving of articles published under the OPEN ACCESS PLUS category. Authors are allowed deposition of such articles on institutional, non-commercial repositories and personal websites immediately after publication on the journal website. This is done under the terms of the Creative Commons Attribution 4.0 International Public License CC-BY 4.0 .

In case of any form of archiving, an acknowledgement must be given to the original source of publication and a link must be inserted to the published article on the journal's/publisher's website. The link to the original source of publication should be provided by inserting the DOI number of the article in the following sentence: "The published manuscript is available at EurekaSelect via https://www.eurekaselect.com/openurl/content.php?genre=article&doi= ."

To ensure permanent access to our publications, Bentham Science has an agreement with Portico to have a long-term preservation of the content published in its journals.

The journal publishes original research, peer-reviewed mini- and full-length review articles, and written in English. Single topic/ thematic issues may also be considered for publication.

These peer-reviewed issues will be restricted to invited or uninvited review/mini-review articles. A Single Topic Issue Editor will offer a short perspective and co-ordinate the solicitation of manuscripts between 3-5 (for a mini-thematic issue) to 6-10 (for full-length thematic issue) from leading scientists. Authors interested in editing a single topic issue in an emerging topic of anti-cancer agents in medicinal chemistry may submit their proposal to the Editor-in-Chief at [email protected] for consideration.

For proposals to publish conference proceedings in this journal, please contact us at email: [email protected]

The length of a published comprehensive review article is from 6000-10000 words with 100 or more references excluding figures, structures, photographs, schemes, tables, etc .

Mini-reviews should be 3000- 6000 words with 75 or more references excluding figures, structures, photographs, schemes, tables etc .

Systematic Reviews include systematic updates on review protocols, methods, research and results from all relevant fields for any studies and updates on already published issues. The total number of words for a published systematic review is from 4000 to 6000 words with 100 or more references excluding figures, structures, photographs, schemes, tables etc . Systematic reviews and meta-analyses must be reported according to PRISMA guidelines; ( www.prisma-statement.org ).

Bentham Science Publishers supports retrospective registration of systematic reviews, in a suitable registry (such as PROSPERO ). The registered systematic review must include the registration number as the last line of the manuscript abstract.

Research articles should be of 4000-6000 words with 75 or more references excluding figures, structures, photographs, schemes, tables, etc .

The articles should be contributed by eminent experts on cutting-edge recent developments. They should be written in the format of mini-reviews (about 4 to 5 pages, approximately 800 to 850 words per composed page excluding tables, structures, graphics, figures and captions) with about 70 references to recent literature. All pages should be numbered sequentially.

Editorials are short papers on important topics related to the journal. The total number of words in an editorial should not exceed 1000 to 1500, and it should contain only 10-15 references. An abstract is not required.

Commentaries present an analysis by scientists on different important issues related to the publications in the journal. Commentaries should contain less than 3000 words, including the abstract, main text, references, and figure legends. However, an abstract is not necessary.

A perspective provides a short overview of a research topic relevant to the field. The length of a published perspective ranges from 1500 to 1800 words, with 20 or more references, excluding figures, structures, photographs, schemes, tables, etc .

Industry News should provide important developments in industries related to the scope of the Journal, that could be of interest to the readers. The length of the submission should be about 1000 words, and it should ideally have 10 or more references (abstract is not required).

Patent News may present important information about recent important patents that have been granted, relevant to the scope of this journal. The length should be about 1000 words, and it should ideally have 10 or more references (abstract is not required).

Position papers are based on thorough research and analysis and aim to influence policy decisions, guide future research directions, or provide guidance to practitioners or stakeholders.

They are short papers on important topics related to the journal. The length of a position paper article is from 3000-4000 words with 40 or more references excluding figures, structures, photographs, schemes, tables, etc.

The manuscript should be written in English in a clear, direct and active style. All pages must be numbered sequentially, facilitating in the reviewing and editing of the manuscript.

It is advisable that authors prepare their manuscript using the template available on the Web, which will assist in preparation of the manuscript according to journal’s format. Download the Template .

Manuscripts submitted for research and review articles in the journal should be divided into the following sections:

Structured Abstract

Graphical Abstract

Text Organization

List of Abbreviations (if any)

Consent for Publication

Availability of Data and Materials

Conflict of Interest

Acknowledgements

Figures/Illustrations (if any)

Chemical Structures (if any)

Tables (if any)

Supportive/Supplementary Material (if any)

The title of the article should be precise and brief and must not be more than 120 characters. Authors should avoid the use of non-standard abbreviations and question marks in titles. The first letter of each word should be in capital letters except for articles, conjunctions and prepositions.

Authors should also provide a short ‘running title’. Title, running title, byline, correspondent footnote and keywords should be written as presented in original manuscripts.

Title page should include paper title, author(s) full name and affiliation, corresponding author(s) names complete affiliation/address, along with phone, fax and email.

The abstract of an article should be a clear, concise and accurate summary, having no more than 250 words, and including the explicit sub-headings (as in-line or run-in headings in bold). Use of abbreviations should be avoided and the references should not be cited in the abstract.

All the original research articles, systematic reviews and meta-analyses must be accompanied by a structured abstract. Ideally, each abstract should include the following sub-headings, but these may vary according to the requirements of the article.

Introduction/Objective: Summarize the objective or purpose of the research in a few sentences.

Methods: Give a brief description of the research design, methodology, and other relevant details about the conduct of the study.

Results: Outline the main conclusions or findings of the study, often with statistical data or significant findings.

Conclusion: Provide an overview of the study's key findings and any implications.

The headings can vary but must state the purpose of the study, details of the participants, measurements, methods, main findings and conclusion.

The headings can vary, but must state the purpose of the study, details of the participants, measurements, methods, main findings and conclusion.

A graphic must be included with each manuscript for use in the Table of Contents (TOC). This must be submitted separately as an electronic file (preferred file types are EPS, PDF, TIFF, Microsoft Word, PowerPoint and CDX etc.). A graphical abstract, not exceeding 30 words along with the illustration, helps to summarize the contents of the manuscript in a concise pictorial form. It is meant as an aid for the rapid viewing of the journals' contents and to help capture the readers attention. The graphical abstract may feature a key structure, reaction, equation, etc. that the manuscript elucidates upon. It will be listed along with the manuscript title, authors names and affiliations in the contents page, typeset within an area of 5 cm by 17 cm, but it will not appear in the article PDF file or in print.

Graphical Abstracts should be submitted as a separate file (must clearly mention graphical abstract within the file) online via Bentham's Manuscript Processing System (MPS).

You can view a few examples of the Graphical Abstracts on our website.

6 to 8 keywords must be provided. Choose important and relevant keywords that researchers in your field will be searching for so that your paper will appear in a database search. The keywords should be contained in the title and they should appear several times in the article. In biomedical fields, MeSH terms are a good ‘common vocabulary’ source to draw keywords from https://www.nlm.nih.gov/mesh/meshhome.html .

The main text should begin on a separate page and should be divided into title page, abstract and the main text. The text may be subdivided further according to the areas to be discussed, which should be followed by the List of Abbreviations, Conflict of Interest, Acknowledgements and Reference sections. For Review Articles, the manuscript should be divided into title page, abstract and the main text. The text may be subdivided further according to the areas to be discussed, which should be followed by the Acknowledgements and Reference sections. The Review Article should mention any previous important recent and old reviews in the field and contain a comprehensive discussion starting with the general background of the field. It should then go on to discuss the salient features of recent developments. The authors should avoid presenting material which has already been published in a previous review. The authors are advised to present and discuss their observations in brief.

For Research Articles the manuscript should begin with the title page and abstract followed by the main text, which must be structured into separate sections as Introduction, Materials and Methods, Results, Discussion, Conclusion, Ethics Approval and Consent to Participate, Human and Animal Rights, Conflict of Interest, Acknowledgements and References .

All randomized clinical trials must include a flow diagram and authors should provide a completed randomized trial checklist (see CONSORT Flow Diagram and Checklist; www.consort-statement.org ) and a trial protocol.

The manuscript style must be uniform throughout the text and 10 pt Times New Roman fonts should be used. The full term for an abbreviation should precede its first appearance in the text unless it is a standard unit of measurement. The reference numbers should be given in square brackets in the text. Italics should be used for Binomial names of organisms (Genus and Species), for emphasis and for unfamiliar words or phrases. Non-assimilated words from Latin or other languages should also be italicized e.g. per se, et al ., etc.

Section headings should be numbered sequentially, left aligned and have the first letter capitalized, starting with the introduction. Sub-section headings however, should be in lower-case and italicized with their initials capitalized. They should be numbered as 1.1, 1.2, etc.

The Introduction section should include the background and aims of the research in a comprehensive manner.

This section provides details of the methodology used along with information on any previous efforts with corresponding references. Any details for further modifications and research should be included. Sufficient details should be provided to the reader about the original data source in order to enable the analysis, appropriateness and verification of the results reported in the study.

It is important for the Methods Section should be sufficiently detailed in respect of the data presented, and the results produced from it. This section should include all the information and protocol gathered for the study at the time when it was being written. If the study is funded or financially supported by an organization to conduct the research, then it should be mentioned in the Methods Section. Methods must be result-oriented. The statement regarding the approval by an independent local, regional or national review committee (e.g. name of ethic committee and institutional review board) should be part of the Methods Section.

Authors who use AI tools for the production of images or graphical elements of the paper, or in the collection and analysis of data, must disclose the use of such tools in the Materials and Methods (or similar section) of the paper, stating how the AI tool was used and which tool was used.

Authors are fully responsible for the content of their manuscript, including parts produced with the assistance of an AI tool, and are thus liable for any breach of publication ethics.

Bentham Science Publishers will assess whether the manner AI was used and declared is reasonable and compliant with its published principles and practices. After publication, content may be rejected or changed due to inadequate declaration or the specific circumstances of its use.

Repeated information should not be reported in the text of an article. A calculation section must include experimental data, facts and practical development from a theoretical perspective.

In research articles, when new compounds are synthesized, 1H and 13C NMR data, and HRMS or microanalysis must be provided as supporting information material. When the cytotoxicities are evaluated, they must be determined on several cancer cell lines and on one healthy cell line. The mechanism of action of the new compounds as potential anti-cancer agents must be investigated. Manuscripts that describe the use of computational modelling and/or molecular docking programs to predict structures or activity of new biologically active compounds will not be considered, unless they contain additional data such as biological testing supporting the modelling (using cells and/or pure protein). In research involving plant material voucher specimens should be deposited in a recognised herbarium. These voucher specimens need to be fully cited within the article (herbarium reference number) along with the origin of the plant material, method of authentication (e.g., expert botanist) and form of the plant material being used.

The important and main findings of the study should come first in the Results Section. The tables, figures and references should be given in sequence to emphasize the important information or observations related to the research. The repetition of data in tables and figures should be avoided. Results should be precise.

This should explore the significance of the results of the work, present a reproducible procedure and emphasis the importance of the article in the light of recent developments in the field. Extensive citations and discussion of published literature should be avoided.

This section of research articles should discuss the implications of the findings in the context of existing research and highlight the study's limitations. The authors should justify the sample size according to the study purpose and methods.

The Results and Discussion may be presented together under one heading of Results and Discussion . Alternatively, they may be presented under two separate sections ( Results Section and Discussion Sections). Short sub-headings may be added in each section if required.

A small paragraph summarizing the contents of the article, presenting the final outcome of the research or proposing further study on the subject, may be given at the end of the article under the Conclusion section.

The authors need to declare the funding sources of their manuscripts clearly by providing the name of the funding agency or financial support along with allotted grant/award number in round brackets (if applied), for instance, “This work was financially supported by [Name of the funding agency] (Grant number XXX).

Similarly, if a paper does not have any specific funding source, and is part of the employment of the authors, then the name of the employer will be required. Authors will have to clearly state that the funder was involved in writing, editing, approval, or decision to publish the article.

Greek symbols and special characters often undergo formatting changes and get corrupted or lost during preparation of manuscript for publication. To ensure that all special characters used are embedded in the text, these special characters should be inserted as a symbol but should not be a result of any format styling (Symbol font face) otherwise they will be lost during conversion to PDF/XML.

Authors are encouraged to consult reporting guidelines. These guidelines provide a set of recommendations comprising a list of items relevant to their specific research design. Chemical equations, chemical names, mathematical usage, unit of measurements, chemical and physical quantity & units must conform to SI and Chemical Abstracts or IUPAC.

All kinds of measurements should be reported only in International System of Units (SI).

In case there is a need to present lengthy, but essential methodological details, use appendices, which can be a part of the article. An appendix must not exceed three pages (Times New Roman, 10 point fonts, 900 max. words per page).The information should be provided in a condensed form, ruling out the need of full sentences. A single appendix should be titled APPENDIX, while more than one can be titled APPENDIX A, APPENDIX B, and so on.

We do encourage to append supportive material, for example a PowerPoint file containing a talk about the study, a PowerPoint file containing additional screenshots, a Word, RTF, or PDF document showing the original instrument(s) used, a video, or the original data (SAS/SPSS files, Excel files, Access Db files etc.) provided it is inevitable or endorsed by the journal's Editor.

Supportive/Supplementary material intended for publication must be numbered and referred to in the manuscript but should not be a part of the submitted paper. In-text citations as well as a section with the heading "Supportive/Supplementary Material" before the "References" section should be provided. Here, list all Supportive/Supplementary Material and include a brief caption line for each file describing its contents.

Any additional files will be linked to the final published article in the form supplied by the author, but will not be displayed within the paper. They will be made available in exactly the same form as originally provided only on our Web site. Please also make sure that each additional file is a single table, figure or movie (please do not upload linked worksheets or PDF files larger than one sheet). Supportive/Supplementary material must be provided in a single zipped file not larger than 4 MB.

Authors must clearly indicate if these files are not for publication but meant for the reviewers'/editors' perusal only.

If abbreviations are used in the text either they should be defined in the text where first used, or a list of abbreviations can be provided.

All potential conflicts of interest (competing interests) that could have a direct or indirect influence on the work must be disclosed by the authors. Even if an author does not have a conflict, disclosing affiliations and interests allows for a more comprehensive and open approach, which leads to a more accurate and objective evaluation of the work. Conflicts of interest, whether genuine or imagined, are a perspective to which the readers are entitled.

The publication of a conflict statement in the article itself, as well as the submission of the conflict disclosure form, is required for all types of papers. It is not necessarily the case that a monetary relationship with examination support or funding for counseling work is inappropriate. Even if the authors do not have any conflict of interest, they still need to provide a confirmation statement in their manuscripts, i.e., “The author(s) confirm(s) that there is no conflict of interest related to the manuscript.”

The following are some examples of potential conflicts of interest that are directly or indirectly related to the research:

Type of support/grant number

Institutional Conflicts of Interest

Funds received by the author

Funds received by the institution

Travel allowances for the research

Funds received for article preparation and reviewing

Funds for conducting review activities

Support provided for article writing assistance, for drugs, equipment, etc

Paid lectures

Pending fund or grant

Financial conflicts of interest can be personal as well as institutional. Personal conflict of interest occurs when a contributor involved in the publication process either receives an amount of money or expects to receive some financial help (including any other financial benefits such as patents or stocks, gifts or services) that may impact the work related to a specific publication. More importantly, in academic research, such financial relationships can lead to institutional conflicts of interest (COIs) because the economic interests of the institution or institutional representatives may unsuitably affect the decision-making process.

An institutional conflict of interest arises in a situation when financial interests of an institution or any institutional official (e.g., investments held by the university in a company) have the potential to unduly influence the research conducted by its employees or students, or pose an unacceptable risk to human subjects. Such conflicts usually arise in a state of affairs where a research project directly offers assistance or a benefit to an external entity via evaluation, validation, trial or test of an invention, product, drug, service or technology, and the institution holds a financial interest with the external entity. Such financial interests incorporate, but are not limited to, receipt of licensing payments or royalties from the external entity, or ownership interest with the external entity. When human subjects are involved in any research project, and the institution supports such a financial interest, the conflict of interest is speculated to be unreasonable.

Non-financial competing interests include (but are not limited to):

In addition, interests other than monetary and any funding (non-financial interests) should be declared if they are relevant to readers. Personal relationships or conflicting interests directly or indirectly related to research, as well as professional interests or personal opinions that may impact your research, are examples of these.

Intellectual property, in basic terms, refers to any intangible property that is the result of creativity, such as patents, copyrights, etc. Similarly, this section seeks to know about copyright and patent (licensed patent, pending or issued) and any payment received for intellectual property, such as:

Licensed Patent

Issued Patent

Pending Patent

All conflict of interest disclosure forms are collected by the corresponding author. It is sufficient for the corresponding author to sign the disclosure form on behalf of all authors in author collaborations when legal agreements for representation allow it. The templates of the form can be found here.

Disclosure form

ICMJE disclosure form

Before the reference list, the corresponding author will include a summary statement in the text of the article that reflects what is reported in the potential conflict of interest disclosure form (s). Author(s) may declare(s) names of reviewers who they think might have a potential conflict of interest; therefore, Editorial Office could avoid inviting such reviewers for an unbiased opinion.

Undisclosed conflict of interest cases before or after the publication of an article are dealt with as per the guidelines of COPE.

Undisclosed conflict of interest in a submitted article (View COPE guidelines)

Undisclosed conflict of interest in a published article (View COPE guidelines)

For more information on COIs, see the guidance from the ICMJE.

Bentham Science tries to conduct a transparent peer-review process with the help of the reviewers who do not have any conflict of interest with the authors. In this connection, reviewers who belong to the same institute or countries as authors are not invited to review manuscripts. However, it is not possible for the Editorial Office to be aware of all competing interests; therefore, it is expected from authors to submit:

List of reviewers who they think have a conflict of interest to ensure a transparent and unbiased review process.

The Editorial Office expects reviewers:

Not to accept manuscript review requests if they have any potential conflict of interest and inform the Editorial Office accordingly.

To decline review requests if they have recently published or submitted an article with any of the authors listed in the manuscript.

To inform the Editorial Office if they have any personal relationship with the authors or work in the same institutes as of authors, which could affect the review transparency.

To abstain from reviewing and informing the Editorial Office/Editor-in-Chief/Handling Editors about any scientific misconduct or fraud, plagiarism, conflict of interest, or any other unethical behavior related to the manuscript, which they found while reviewing it.

During the submission of review comments, reviewers are asked to reconfirm that they do not have any conflict of interest related to the article. After confirming the below statement, they can submit their comments.

“I hereby confirm that I don’t have any conflict of interest related to the manuscript.”

If, however, there are still any remaining interests, then reviewers must mention those in the ‘Confidential’ section of the review form.

Reviewers are not encouraged to contact authors directly regarding any of their conflicts of interest. Peer reviewers should follow journals’ policies in situations they consider to represent a conflict to reviewing.

If reviewers intentionally undisclosed any conflict of interest, then they will be blacklisted for any future peer reviewing activity of the journal.

The Editorial Office always ensures that an author, if added after peer review activity of a manuscript, is not part of the reviewers’ list who have conducted a peer review of the same manuscript.

Editors must not review submitted manuscripts if they have any personal, professional or financial involvement/conflict of interest with the authors of the manuscript. Every participant involved in the peer review process, including editorial board members, reviewers, and editors, must declare any potential conflicts of interest to ensure a transparent and unbiased review activity.

Editors-in-Chief or Editors who are responsible for the initial and final decision should recuse themselves to review or take decisions on any manuscript that is written by authors affiliated to the same institute as of editor, or if they have been a family member, competitor, collaborator, or have published any manuscript in last 3 years with the authors associated with the manuscript. They can however nominate someone else on the Board who could provide a neutral opinion on the manuscript.

The Editorial office recommends editors to follow COPE and WAME guidelines to process such manuscripts which involves their personal relationship.

Manuscripts submission by an Editor/Editor-in-Chief

The initial and final decision on the manuscripts submitted by an Editor/Editor-in-Chief will be taken by any other member of the Board. The Editorial Office will identify members who do not have any potential conflict of interest with the Editor or Editor-in-Chief.

Any research assistants or other individuals who assisted with the research but are not listed as authors, such as those who carried out the literature review, produced, computerized, and analyzed the data, or helped with the language, writing, or proofreading of the article, or offered any comments or suggestions, should be acknowledged. Briefly, everyone who has contributed significantly to the improvement of the paper should be acknowledged. It is recommended to mention the "Declared None" if there is no acknowledgement for the study.

Guest or honorary authorship based solely on position (e.g. research supervisor, departmental head) is discouraged.

The specific requirements for authorship have been defined by the International Committee of Medical Journal Editors ( www.icmje.org ). Examples of authors' contributions are: 'designed research/study', 'performed research/study', 'contributed important reagents', 'collected data', 'analyzed data', 'wrote paper' etc. This information must be included in the submitted manuscript as a separate paragraph under the heading 'Authors' Contribution'. The corresponding author is responsible for obtaining permission from all co-authors for the submission of any version of the manuscript and for any changes in the authorship.

All clinical investigations should be conducted according to the Declaration of Helsinki principles. For all manuscripts reporting data from studies involving human participants, formal review and approval by an appropriate institutional review board or ethics committee are required.

Compliance with the guidelines of the International Committee of Medical Journal Editors ( www.icmje.org ) is recommended, in accordance with the patient’s consent for research or participation in a study as per the applicable laws and regulations regarding the privacy and/or security of personal information, including, but not limited to, the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and other U.S. federal and state laws relating to confidentiality and security of personally distinguishable evidence, the General Data Protection Regulation (GDPR) (EU) 2016/679 and member state implementing legislation, Canada's Personal Information Protection and Electronic Documents Act, India's Information Technology Act and related Privacy Rules, (together "Data Protection and Privacy Laws").

It is the responsibility of the author to ensure that:

Patients' names, initials, or hospital numbers are not mentioned anywhere in the manuscript (including figures).

Authors are responsible for obtaining the patient consent-to-disclose forms for all recognizable patients in photographs, videos, or other information that may be published in the Journal, in derivative works, or on the journal’s website and for providing the manuscript to the recognizable patient for review before submission.

The consent-to-disclose form should indicate specific use (publication in the medical literature in print and online, with the understanding that patients and the public will have access) of the patient's information and any images in figures or videos, and must contain the patient's signature or that of a legal guardian along with a statement that the patient or legal guardian has been offered the opportunity to review the identifying materials and the accompanying manuscript.

If the manuscript has an individuals’ data, such as personal details, audio-video material, etc ., consent should be obtained from that individual. In case of children, consent should be obtained from the parent or the legal guardian.

A specific declaration of such approval and consent-to-disclose form must be made in the copyright letter and in a stand-alone paragraph at the end of the article especially in the case of human studies where inclusion of a statement regarding obtaining the written informed consent from each subject or subject's guardian is a must. The original should be retained by the guarantor or the corresponding author. Editors may request to provide the original forms by fax or email.

All such case reports require by a proper consent being obtained prior to publishing. Please refer COPE guidelines available at https://publicationethics.org/resources/guidelines/journals%E2%80%99-best-practices-ensuring-consent-publishing-medical-case-reports .

Editors may request that authors provide documentation of the formal review and recommendation from the institutional review board or ethics committee responsible for oversight of the study. The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the above-mentioned requirements.

Anonymous images, that do not identify the individual directly or indirectly, such as through any identifying marks or text, do not require formal consent, for example, X-rays, ultrasound images, pathology slides or laparoscopic images.

In case consent is not obtained, concealing the identity through eye bars or blurring the face would not be acceptable.

For research involving animals, the authors should indicate whether the procedures followed were in accordance with the standards set forth in the eighth edition of “Guide for the Care and Use of Laboratory Animals” ( grants.nih.gov/grants/olaw/guide-for-the-care-and-use-of-laboratory-animals_prepub.pdf published by the National Academy of Sciences, The National Academies Press, Washington, D.C.).

Research work on animals should be carried out in accordance with the NC3Rs ARRIVE Guidelines. For In Vivo Experiments, please visit https://www.nc3rs.org.uk/arrive-guidelines

Authors should clearly state the name of the approval committee, highlighting that legal and ethical approvals were obtained prior to initiation of the research work carried out on animals, and that the experiments were performed in accordance with the relevant guidelines and regulations stated below.

US authors should cite compliance with the US National Research Council's " Guide for the Care and Use of Laboratory Animals "

The US Public Health Service's " Policy on Humane Care and Use of Laboratory Animals " and " Guide for the Care and Use of Laboratory Animals "

UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039) .

European authors outside the UK should conform to Directive 2010/63/EU .

Research in animals must adhere to ethical guidelines of the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines .

The manuscript must clearly include a declaration of compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or relevant permissions or licences obtained by the IUCN Policy Statement on Research Involving Species at Risk of Extinction and the Convention on the Trade in Endangered Species of Wild Fauna and Flora. .

If a study is exempted from ethics approval, authors must indicate the reasons for exemption in the ethical statement.

Following is an example of Ethical Statements:

"This study involving animal subjects is exempted from ethics approval for [specific reasons]. The exemption was evaluated and authorized by [Full name of ethics committee], ensuring adherence to ethical standards”.

Client-owned animals (non-commercially available animals such as pets or livestock) should be studied exercising best practices in veterinary care. Authors must confirm that the owner(s) (or their legal representatives) have provided written consent for this purpose.

"The animal study was evaluated and authorized by [Full name of the ethics committee]. The owners provided written informed consent for their animals' involvement in this study, ensuring ethical treatment and compliance with standards."

Studies involving animals must comply with internationally accepted standards and adhere to the 3Rs principles (Replace, Reduce, Refine).

• Replace: Whenever possible, replace animals with alternatives.
• Reduce: Reducing the number of animals used and
• Refine: Refining experimental settings can reduce animal damage.

Authors are encouraged to follow the ARRIVE guidelines (Reporting in Vivo Experiments) for reporting experiments involving live animals.

An example of Ethical Statements:

"This study adheres to internationally accepted standards for animal research, following the 3Rs principle. The ARRIVE guidelines were employed for reporting experiments involving live animals, promoting ethical research practices."

Studies on euthanasia, including chloral hydrate, ether, and chloroform overdose, are severely discouraged. Authors should include an in-depth description of any anesthetic, surgical, or euthanasia procedures conducted throughout the study.

If the experimental details explained in the study violate the standard animal research procedure, editors may seek extra documentation, such as approval forms and relevant literature citations.

All experimental research on plants (either cultivated or wild), should comply with international guidelines. The manuscript should include a declaration of compliance of field studies with relevant guidelines and/or relevant permissions or licenses obtained by the IUCN Policy Statement on Research Involving Species at Risk of Extinction and the Convention on the Trade in Endangered Species of Wild Fauna and Flora.

All experimental research on plants (either cultivated or wild), should comply with international guidelines. The manuscript should include a declaration of compliance of field studies with relevant guidelines and/or relevant permissions or licenses obtained by the IUCN Policy Statement on Research Involving Species at Risk of Extinction and the Convention on the Trade in Endangered Species of Wild Fauna and Flora .

Any unusual risks associated with the use of any chemicals, procedures, or equipment used in the work must be explicitly stated by the author in the manuscript, preferably in both the materials and methods section and the declaration section. For more information, visit The World Medical Association ( https://www.wma.net/what-we-do/public-health/chemicals )

We strive to promote gender and sex equity in research and adhere to the guidelines of Sex and Gender Equity in Research (SAGER) to ensure inclusivity and rigor of the work. All authors submitting research papers are required to follow the Sex and Gender Equity in Research (SAGER) guidelines . These guidelines are intended to encourage the inclusion of sex and gender considerations in research in order to improve the rigor and relevance of our publications.

The SAGER guidelines for reporting sex and gender information in methodology or study design, data analysis, results, and interpretation of findings are strongly encouraged. Authors of review articles are advised to address the methods used for selecting, locating, extracting, and synthesizing data; systematic reviews are required to do so.

Bentham Science expects all contributors to respect values of justice, benevolence, and autonomy when conducting research. We understand that certain situations such as medical emergencies or humanitarian crises may differ from non-emergency scenarios. Bentham Science recommends that research efforts should not hurt human subjects/respondents or the researchers, and should be conducted with sufficient scientific rigor as permissible in these situations, respectively. Care should be taken to address potential problems faced by persons who may be victims of disasters or involved in a medical emergency. These are vulnerable individuals and their privacy and dignity should be respected. Researchers should make note of this in their research and identify potential issues in their work that may arise because of such situations. Research directed in emergency circumstances should be to the greatest advantage of survivors involved in the research and with the goal of minimizing any future casualties. For guidance, the essential requirements of research in emergency situation are the preservation of human life, wellbeing and security, along with the rights to protection, privacy and confidentiality of subjects.

Unethical behavior and misconduct may be pointed out by anyone to the Editor and Publisher with sufficient evidences. The Editor, in consultation with the Publisher, will initiate investigation against this Unethical misconduct, complete the procedure till an unbiased decision is reached, and maintain confidentiality throughout the process of the investigation. The Author should be given the opportunity to reply to all minor or major accusations.

In case of serious breaches, the employer may be informed where appropriate, by the Editor/Publisher, after reviewing all available information and evidences or after seeking help from experts in that field.

Author(s) and Reviewers must be informed in case of misinterpretation or mishandling of International Acceptable Standards

A strict notice should be sent to the author and reviewer to avoid future unethical misconduct

An Editorial on the reported misconduct should be published or official notice of unethical behavior should be posted on the website

Official letter about this misconduct should be issued to the Head of Departments, Funding Agencies of the accused author and the reviewer, as well as Abstracting & Indexing Agencies.

Where required, retraction and withdrawal of publication may be undertaken from the Publisher’s journal in discussion with the Head of the Department of the author or reviewer, and other higher authorities should be informed

The Publisher may impose restrictions for some period on future publications from the accused author in the journals

If the manuscript has an individuals’ data, such as personal detail, audio-video material etc., consent should be obtained from that individual.

A specific declaration of such approval and consent-to-disclose form must be made in the copyright letter and in a stand-alone paragraph at the end of the article especially in the case of human studies where inclusion of a statement regarding obtaining the written informed consent from each subject or subject's guardian is a must. The original should be retained by the guarantor or corresponding author. Editors may request to provide the original forms by fax or email.

Post-publication discussions are well-timed and engaging scientific remarks and justifications on research articles published in "Anti-Cancer Agents in Medicinal Chemistry" . These remarks must be based on the information concurrent with the original study and not on the scientific advancements being made subsequently.

Manuscript Preparation, Submission & Editorial Process:

• Post-publication discussion should commence with a short paragraph that outlines the summary of the article.
• Authors are advised to avoid using inciting tone in the comments and keep the message clear and concise.
• The main text should not exceed 1200 words with up to 15 references and may include one or two figures and/or tables.
• References should be submitted in the ACS or Vancouver style.
• The correspondents are recommended to contact the original authors first prior to submitting their comments to the journal as this may resolve the issues that may have arisen due to some misunderstanding.
• The correspondence that has been done with the authors should also be submitted as an attachment with the manuscript.

Any queries therein should be addressed to [email protected]

The NIH acknowledges the misidentification and/or cross-contamination of cell cultures e.g. HeLa cells being used in a research study as a serious problem. In order to ensure the validation of the work and proper utilization of resources, it is a prerequisite that correct reagents be used in studies dealing with established human (tumor) cell lines that have been cultured for more than 4 years up to the date of submission of the manuscript. Cell lines such as short-term cultures of human tumors, murine cell lines (as a catalog of DNA profiles is not yet available) and tumor cell lines established in the course of the study that is being submitted, are presently exempt from this rule. To minimize the risk of working with misidentified and/or contaminated cell lines, tests such as isoenzyme analysis, karyotyping/cytogenetic analysis and, more recently, molecular techniques of DNA profiling may be carried out to authenticate cell cultures. These tests may help confirm or establish the identify profile for a cell line. Bentham Science recommends that all cell lines be authenticated prior to submitting a paper for review. Authors are therefore required to provide authentication of the origin and identity of the cells by performing cell profiling either in their own laboratory or by outsourcing an approved laboratory or cell bank. Authentication is required when a new line is established or acquired, before freezing a cell line, if the performance of the line is not consistent or results are unexpected, if using more than one cell line, and before publication of the study.

The cell lines profile should be cross-checked with the profile of the donor tissue of other continuous cell lines such as provided by the authentic data bank such as DSMZ ( www.dsmz.de/fp/cgi-bin/str.html ), ATCC® ( https://www.atcc.org/en/Products/Cells_and_Microorganisms.aspx ) etc .

References should be submitted preferably in the ACS or Vancouver style. All references must be complete and accurate. The reference numbers must be finalized and the bibliography must be fully formatted before submission.

The references should be relevant to the study and should refer to the original research sources. Self-citation and self-interest should be avoided by the authors, editors, and peer-reviewers.

See below few examples of references listed in the ACS and Vancouver Style:

In ACS style, all references should be numbered sequentially [in square brackets] in the text and listed in the same numerical order in the reference section. Superscript in the in-text citations and reference section should be avoided.

Different reference formats have different rules for citation. See below for some common format examples.

The minimum required information for a journal article reference is author, abbreviated journal title, year, publication, volume number, and initial page of cited article, though complete pagination is possible. Journal abbreviation and volume are italicized . Year of publication is bold . All authors must be cited and there should be no use of the phrase et al. Journal abbreviations should follow the Index Medicus/MEDLINE.

Bard, M.; Woods, R.A.; Bartón, D.H.; Corrie, J.E.; Widdowson, D.A. Sterol mutants of Saccharomyces cerevisiae : chromatographic analyses. Lipids , 1977 , 12 (8), 645-654.

Zhang, W.; Brombosz, S.M.; Mendoza, J.L.; Moore, J.S. A high-yield, one-step synthesis of o-phenylene ethynylene cyclic trimer via precipitation-driven alkyne metathesis. J. Org. Chem. , 2005 , 70 , 10198-10201.

Crabtree, R.H. The Organometallic Chemistry of the Transition Metals , 3 rd ed.; Wiley & Sons: New York, 2001 .

Wheeler, D.M.S.; Wheeler, M.M. D. Stereoselective Syntheses of Doxorubicin and Related Compounds In: Studies in Natural Products Chemistry ; Atta-ur-Rahman, Ed.; Elsevier Science B. V: Amsterdam, 1994 ; Vol. 14 , pp. 3-46.

Jakeman, D.L.; Withers, S.G.E. In: Carbohydrate Bioengineering: Interdisciplinary Approaches , Proceedings of the 4 th Carbohydrate Bioengineering Meeting, Stockholm, Sweden, June 10-13, 2001; Teeri, T.T.; Svensson, B.; Gilbert, H.J.; Feizi, T., Eds.; Royal Society of Chemistry: Cambridge, UK, 2002 ; pp. 3-8.

National Library of Medicine. Specialized Information Services: Toxicology and Environmental Health. sis.nlm.nih.gov/Tox/ToxMain.html (Accessed May 23, 2004 ).

Hoch, J.A.; Huang, S. Screening methods for the identification of novel antibiotics. U.S. Patent 6,043,045, March 28, 2000.

Mackel, H. Capturing the Spectra of Silicon Solar Cells . PhD Thesis, The Australian National University: Canberra, December 2004 .

Citations for articles/material published exclusively online or in open access (free-to-view), must contain the accurate Web addresses (URLs) at the end of the reference(s), except those posted on an author’s Web site (unless editorially essential), e.g. ‘Reference: Available from: URL’.

Some important points to remember

All authors must be cited and there should be no use of the phrase et al.

Date of access should be provided for online citations.

Punctuation should be properly applied as mentioned in the examples given above.

Abstracts, unpublished data and personal communications (which can only be included if prior permission has been obtained) should not be given in the references section. The details may however appear in the footnotes.

The authors are encouraged to use a recent version of EndNote (version 5 and above) or Reference Manager (version 10) when formatting their reference list, as this allows references to be automatically extracted.

In Vancouver style, all references should be numbered sequentially [in square brackets] in the text and listed in the same numerical order in the reference section. Punctuation should be properly applied as mentioned in the examples given above.

The required information for a journal article is author, abbreviated journal title, year, publication, volume number, and initial page of cited article, though complete pagination is possible. It is necessary to list all authors if the total number of author is six or less and for more than six authors use three authors and then et al (the term " et al. " should be in italics). Journal abbreviations should follow the Index Medicus/MEDLINE. Capitalize the first letter of the first word in the title. The rest of the title is in lower-case, with the exception of proper names.

Al-Habian A, Harikumar PE, Stocker CJ, Langlands K, Selway JL. Histochemical and immunohistochemical evaluation of mouse skin histology: comparison of fixation with neutral buffered formalin and alcoholic formalin. J Histotechnol. 2014 Dec;37(4):115-24.

Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006 May 11;354(19):1985-1997.

Blaxter PS, Farnsworth TP. Social health and class inequalities. In: Carter C, Peel JR, Eds. Equalities and inequalities in health. 2nd ed. London: Academic Press 1976; pp. 165-78.

Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, Eds. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press 1995; pp. 465-78.

Larsen CE, Trip R, Johnson CR. Methods for procedures related to the electrophysiology of the heart. US Patent 5529067, 1995.

Kimura J, Shibasaki H, Eds. Recent advances in clinical neurophysiology. Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology; 1995 Oct 15-19; Kyoto, Japan. Amsterdam: Elsevier 1996.

Borkowski MM. Infant sleep and feeding: a telephone survey of Hispanic Americans. PhD dissertation. Mount Pleasant (MI): Central Micihigan University 2002.

Aylin P, Bottle A, Jarman B, Elliott, P. Paediatric cardiac surgical mortality in England after Bristol: descriptive analysis of hospital episode statistics 1991-2002. BMJ [serial on the Internet]. 2004 Oct 9; [cited: 15 October 2004]; 329: [about 10 screens]. Available from: sis.nlm.nih.gov/Tox/ToxMain.html

Frangioni G, Bianchi S, Fuzzi G, Borgioli G. Dynamics of hepatic melanogenesis in newts in recovery phase from hypoxia. Open Zoo J 2009; 2: 1-7. Available from: https://benthamopen.com/ABSTRACT/TOZJ-2-1 [cited: 26 th Jan 2009]

Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. Am J Nurs [serial on the Internet]. June 2002 [cited: 12 th Aug 2002]; 102(6): [about 3 p.]. Available from: www.nursingworld.org/AJN/2002/june/Wawatch.htm.

Avoid using superscript in the in-text citations and reference section.

The source of data and materials should be mentioned in the manuscript, in support of the findings. Sharing research data is integral to its transparency and reproducibility. Data sharing involves the citation and availability of data that support the findings of the research.

Bentham Science encourages authors to share the source of data and materials in the manuscript, in support of the findings.

The four types of research data policies are mentioned below.

Case 1: Data sharing and data citation

Case 2: Data sharing and its evidence

Case 3: Statement for Data sharing and data availability

Case 4: Data sharing, evidence of data sharing and data for peer-review

Wherever appropriate and possible, the journal encourages authors to publish data to support their research findings in a public repository. Any datasets mentioned in the article that are available in external repositories should be cited.

How to Cite the Data?

Whether the data was developed by the author(s) or researcher(s), all publicly available data referenced in the preparation of an article should be cited in the text and reference list. The references relating to the data availability should be presented in the following format:

Example: Name of author(s), the title of data set, data repository, document version (e.g., most recent updated version), Digital Object Identifier (DOI), and Bentham Science reference style should be included in data citations.

When authors submit a paper to a journal, the authors agree that the data provided in the publication, including the relevant raw data, will be freely available to any researcher who wants to use these for non-commercial reasons without jeopardising participant anonymity.

Data availability declarations are required under Bentham Science research data policy types.

The statement relating to the data availability should be presented in the following format under a separate section for ‘Availability of Data and Materials’ in the manuscript:

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

The data that support the findings of this study are available from the corresponding author, [author initials], on special request.

The datasets generated or analysed during the current study are not publicly available due to [mention the reason(s)].

Authors who do not wish to share their data should clearly state that the data will not be shared, and thus mention as ‘Not applicable’.

The statement relating to the data should be presented in the following format:

"The data supporting the findings of the article is available in the [repository name] at [URL], reference number [reference number]”.

Additional Data Availability Statements

Authors can add or change the statement(s) above, to fit their work the best. Depending on the nature of the research, several assertions may need to be merged.

All datasets on which the paper's conclusions are based must be made accessible to reviewers and readers, according to the journal's rules. Prior to peer review, authors must either deposit their datasets in publicly accessible repositories or provide them as supplementary materials with their submission. For further details, please visit complete guidelines at: http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html

Authors may provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data. if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

The Authors are encouraged to use industry-recognized reporting guidelines for biomedical and biological research, if applicable, to explain that all requirements for reporting have been adopted.

All authors must strictly follow the reporting guidelines below for preparing the study for publication.

CONSORT: All randomized clinical trials must include a flow diagram and authors should provide a completed randomized trial checklist (see CONSORT Flow Diagram and Checklist; www.consort-statement.org ) and a trial protocol. For further details, please visit complete guidelines at: http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html

STARD and TRIPOD: Studies of diagnostic accuracy must be reported according to STARD guidelines; ( www.stard-statement.org ) and TRIPOD guidelines; ( www.tripod-statement.org )

STROBE: Observational studies (cohort, case-control, or cross-sectional designs) must be reported according to the STROBE statement, and should be submitted with their protocols; ( www.strobe-statement.org ).

CARE: Case report must be reported according to CARE guidelines; ( www.care-statement.org )

COREQ: Qualitative research must be reported according to COREQ guidelines; ( academic.oup.com/intqhc/article/19/6/349/1791966 )

CHEERS: Economic evaluations must be reported according to CHEERS guidelines; ( www.bmj.com/content/346/bmj.f1049 )

STREGA: Genetic association studies must be reported according to STREGA guidelines; ( www.medicine.uottawa.ca )

PRISMA: Systematic reviews and meta-analyses must be reported according to PRISMA guidelines; ( www.prisma-statement.org )

MOOSE: Meta-analyses of observational studies in epidemiology must be reported according to MOOSE guidelines ( http://www.ijo.in/documents/14MOOSE_SS.pdf )

EQUATOR: To find the reporting guidelines see ( www.equator-network.org )

All authors must strictly follow the guidelines below for preparing illustrations for publication in Anti-Cancer Agents in Medicinal Chemistry . If the figures are found to be sub-standard, then the manuscripts will be rejected.

The authors are expected to submit good quality figure(s) in PDF, PPT, MS Word, TIFF or JPEG versions, which, if required, should be improved yourself or by professional graphic designers of your organization/country. You may even consider approaching our contracted service provider Eureka Science for Graphics Enhancement Services.

The Graphics Designing team at Eureka Science can assist in improving the quality of your images at affordable rates. Eureka Science has contracted special rates with us of US $155 for the improvement of up to five figures, with any additional figures being charged at US $25 each.

The quality of Graphic Enhancement Services offered by Eureka Science can be viewed at http://www.eureka-science.com/images/Binder1.pdf , along with valuable feedback on their services at http://www.eureka-science.com/testimonials.php . You may contact Eureka Science at [email protected]

Note: Availing Graphics Enhancement Services does not guarantee acceptance of the manuscript for publication. The final acceptance/decision on the manuscript is taken by the EiC.

Illustrations must be provided according to the following guideline:

Illustrations should be embedded in the text file, and must be numbered consecutively in the order of their appearance. Each figure should include only a single illustration which should be cropped to minimize the amount of space occupied by the illustration.

If a figure is in separate parts, all parts of the figure must be provided in a single composite illustration file.

Photographs should be provided with a scale bar if appropriate, as well as high-resolution component files.

All the numbers, symbols and letters in figures should be consistent and clear throughout and large enough to remain readable when the size is reduced for publication.

It must be ensured to cite each figure in the text in sequence.

Line Art image type is normally an image based on lines and text. It does not contain tonal or shaded areas. The preferred file format should be TIFF or EPS, with the color mode being Monochrome 1-bit or RGB, in a resolution of 900-1200 dpi.

Halftone image type is a continuous tone photograph containing no text. It should have the preferred file format TIFF, with color mode being RGB or Grayscale, in a resolution of 300 dpi.

Combination image type is an image containing halftone , text or line art elements. It should have the preferred file format TIFF, with color mode being RGB or Grayscale, in a resolution of 500-900 dpi.

Illustrations may be submitted in the following file formats:

Illustrator

EPS (preferred format for diagrams)

PDF (also especially suitable for diagrams)

PNG (preferred format for photos or images)

Microsoft Word (version 5 and above; figures must be a single page)

PowerPoint (figures must be a single page)

JPEG (conversion should be done using the original file)

CDX (ChemDraw)

TGF (ISISDraw)

Bentham Science does not process figures submitted in GIF format.

For TIFF or EPS figures with considerably large file size restricting the file size in online submissions is advisable. Authors may therefore convert to JPEG format before submission as this results in significantly reduced file size and upload time, while retaining acceptable quality. JPEG is a ‘lossy’ format, however. In order to maintain acceptable image quality, it is recommended that JPEG files are saved at High or Maximum quality.

Zipit or Stuffit tools should not be used to compress files prior to submission as the resulting compression through these tools is always negligible.

Please refrain from supplying:

Graphics embedded in word processor (spreadsheet, presentation) document.

Optimized files optimized for screen use (like GIF, BMP, PICT, WPG) because of the low resolution.

Files with too low resolution.

Graphics that are disproportionately large for the content.

Requirement
Width=8.5 inches (In-between the required size)
Height=11 inches (In-between the required size)
Pixels/Inches=300 (minimum dpi)
All figures should be in vector scale (except half tone, photograph.)

There are many software packages, many of them freeware or shareware, capable of converting to and from different graphics formats, including PNG.

General tools for image conversion include Graphic Converter on the Macintosh, Paint Shop Pro, for Windows, and ImageMagick, available on Macintosh, Windows and UNIX platforms.

Bitmap images (e.g. screenshots) should not be converted to EPS as they result in a much larger file size than the equivalent JPEG, TIFF, PNG or BMP, and poor quality. EPS should only be used for images produced by vector-drawing applications such as Adobe Illustrator or CorelDraw. Most vector-drawing applications can be saved in, or exported as, EPS format. If the images were originally prepared in an Office application, such as Word or PowerPoint, original Office files should be directly uploaded to the site, instead of being converted to JPEG or another format of low quality.

The cost for each individual page of color figures/plates/illustrations is US $1,280 .

Color figures should be supplied in CMYK and not RGB colors.

Note for authors To maintain publication quality, figures submitted in colour will be published in colour only.

Chemical structures must be prepared in ChemDraw (CDX file) and provided as separate file.

[As according to the ACS style sheet]

Chain angle	120°
Bond spacing	18% of width
Fixed length	14.4 pt (0.500cm, 0.2in)
Bold width	2.0 pt (0.071cm, 0.0278in)
Line width	0.6 pt (0.021cm, 0.0084in)
Margin width	1.6 pt (0.096cm)
Hash spacing	2.5 pt (0.088cm, 0.0347in)
Font	Times New Roman
Size	10 pt
Units	points
Tolerances	3 pixels
Paper	US letter
Scale	100%

Data Tables should be submitted in Microsoft Word table format.

Each table should include a title/caption being explanatory in itself with respect to the details discussed in the table. Detailed legends may then follow.

Table number in bold font i.e . Table 1 , should follow a title. The title should be in small case with the first letter in caps. A full stop should be placed at the end of the title.

Tables should be embedded in the text exactly according to their appropriate placement in the submitted manuscript.

Columns and rows of data should be made visibly distinct by ensuring that the borders of each cell are displayed as black lines.

Tables should be numbered in Arabic numerals sequentially in order of their citation in the body of the text.

If a reference is cited in both the table and text, please insert a lettered footnote in the table to refer to the numbered reference in the text.

Tabular data provided as additional files can be submitted as an Excel spreadsheet.

It is adequate to present data in Tables to avoid unnecessary repetition and reduce the length of the text.

The citation of each table in the text must be ensured.

Symbols and nonstandard abbreviations should be explained in the end of the text.

All references should be numbered sequentially [in square brackets] in the table and listed in the same numerical order in the reference section.

Bentham Science Publishers requires that all individuals listed as authors must have made a substantial contribution to the design, performance, analysis, or reporting of the work. The role of authors is judged on the basis of ICMJE and COPE guidelines.

All contributing authors are required to sign a copyright letter, mentioning complete details, including full name, affiliation, email address, ORCID ID and their role in the article. After successful electronic submission of a manuscript, a system-generated acknowledgements will be sent to all authors on their provided email addresses.

The corresponding author must have the approval of all other listed authors for the submission and publication of all versions of the manuscript.

Authors are strongly recommended to use their ORCID ID when submitting an article for consideration. Alternatively, they can acquire an ORCID ID via the submission process. For more information about ORCID IDs, visit here.

At the time of initial submission, the finalized list of authors in the correct sequence should be provided, which will not be changed once the publication process starts.

In exceptional cases, requests for the addition/deletion of an author may be considered by the publisher subject to a) written approval from all co-authors and b) a strong justification (which may or may not be accepted by the Publisher).

Here is some advice from COPE on authorship issues. Bentham strives to follow these guidelines.

Advice on how to spot authorship problems

Corresponding author requests addition of extra author before publication

Corresponding author requests removal of the author before publication

Request for addition of extra author after publication

Request for removal of author after publication

Bentham Science Publishers recognizes that authors use a variety of tools for preparing articles related to their scientific works, ranging from simple ones to very sophisticated ones.

According to the COPE (Committee on Publication Ethics) guidelines, "AI tools cannot meet the requirements for authorship as they cannot take responsibility for the submitted work. As non-legal entities, they cannot assert the presence or absence of conflicts of interest nor manage copyright and license agreements" .

The pertinence of such tools may vary and evolve with public opinion, due to which the use of AI-powered language tools has led to a significant debate. These tools may generate useful results, but they can also lead to errors or misleading results; therefore, it is important to know which tools were used for evaluating and interpreting a particular scientific work.

Considering the above we require that:

• The authors to report any significant use of such tools in their works, such as instruments and software along with text-to-text generative AI consistent with subject standards for methodology.
• All co-authors should sign a declaration that they take full responsibility for all of its contents, regardless of how the contents were generated. Inappropriate language, plagiarized and biased contents, errors, mistakes, incorrect references, or misleading content generated by AI language tools and the relevant results reported in scientific works are the full and shared responsibility of all the authors, including co-authors.
• AI language tools should not be listed as an author; instead, authors should follow clause (1) above.

Activities such as the acquisition of funding, general supervision of a research group or general administrative support, writing assistance, technical editing, language editing, and proofreading alone do not qualify any contributor for authorship. Such contributors may be acknowledged individually or together as a group in the acknowledgement section. Further details for writing acknowledgements are available here. Persons not meeting authorship criteria can be acknowledged in the acknowledgement section of the article rather than being enlisted as authors.

All contributing authors should contribute substantially to the article and sign the copyright letter. Bentham Science Publishers discourages authorship based solely on position (e.g., a research supervisor or a departmental head). We use COPE guidelines for identifying any suspected ghost, guest or gift authorship.

Manuscripts containing language inconsistencies will not be published. Authors should seek professional assistance for correction of grammatical, scientific and typographical errors before submission of the revised version of the article for publication. Professional editing services may also be sought by the team available at Bentham Science .

Authors will receive page proofs of their accepted paper before publications. To avoid delays in publication, proofs should be checked immediately for typographical errors and returned within 48 hours . Major changes are not acceptable at the proof stage.

The corresponding author will be solely responsible for ensuring that the revised version of the manuscript incorporating all the submitted corrections receives the approval of all the co-authors of the manuscript.

No page charges will be levied to authors for the publication of their review articles. For published research articles, however, the publication charges are US $390.

Bentham Science offers a 50% discount off all page charges for manuscripts of all corresponding authors who reside in countries which are categorized as low-income economies by the World Bank. To see if you qualify to the discount, please refer to the complete list of these countries click here

Publication Charges only become due after an article has been both reviewed and accepted for publication. Therefore, submission of an article is not a guarantee that it will be published. The final decision on the manuscript is made by the Editor-in-Chief on the basis of at least two independent peer-review reports.

Other service fees for activities such as Quick Track Services, Open Access Plus, Animated Abstracts, Color Figure, Figure Improvement or Language Editing are optional and are only charged as and when these services are availed.

For this journal an optional fast publication fee-based service called QUICK TRACK is available to authors for their submitted manuscripts. Authors who opt for this fee-based service do not have to pay any additional page charges.

QUICK TRACK allows online publication within 2 weeks of receipt of the final approved galley proofs from the authors. Similarly the manuscript can be published in the next forthcoming PRINT issue of the journal. The total publication time, from date of first receipt of manuscript to its online publication is 10 weeks, subject to its acceptance by the referees and modification (if any) by the authors within one week.

The author will be initially charged a small fee on receipt of the agreement form for Quick Track publication to partially cover the initial costs incurred for expedited processing of the submitted manuscript. Later, the full Quick Track publication fee ( US $4395 per article charges) will be payable in advance, after acceptance of the manuscript, before online publication of the article. However, if the article is rejected at the peer-review stage, then the US $4395 per article charges will not be charged.

Please note that whether the author opts for the QUICK TRACK facility or not, standard reviewing practices will be followed, which will not in any way affect the acceptance or rejection of the manuscript by the reviewers.

Authors who have availed Quick Track service in a BSP journal will be entitled for an exclusive 30% discount if they again wish to avail the same service in any BSP journal.

For more information please contact the Editorial Office by e-mail at [email protected]

Bentham Science offers a 50% discount off the Quick Track Publication Fee for manuscripts of all corresponding authors who reside in countries which are categorized as low-income economies by the World Bank. To see if you qualify to the discount, please refer to the complete list of these countries click here .

Bentham Science offers three major services related to its publications:

• Subscription services (to subscribers, institutes, libraries, customers, etc.): Involving access to published content based on certain charges for corporates, academic institutes, and individuals.
• Editorial/Author Pre-publication services (to editors, authors, etc.): Quick track processing, language editing, etc.
• Editorial/Author Post-publication Promotional Services (to authors, institutions and organizations): Open Access Plus, Animated Abstracts, Sharing PDF on KUDOS, reprints, etc.

Since these services are optional in nature and are offered for specific services rendered, hence refunds are not allowed against the availed and charged services, except under special cases.

Bentham Science also offers authors the option of “Open Access Plus (Gold Open Access)” for publishing their articles. The article processing charges are US $3645 per article for general submissions and US $1900 per article for those published within thematic issues.

This paid service allows authors to disseminate their work to a much wider audience in compliance with the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0) ( https://creativecommons.org/licenses/by/4.0/legalcode ). Under this license, authors are asked to indicate whether they wish to pay for the service in order to make their article more widely available on an “Open Access Plus (Gold Open Access)” basis. Where an author does not opt-in for this paid service, the article will be published under the standard subscription-based mode.

Authors who select the “Quick Track” publication option and also wish to have their article made available on an “Open Access Plus (Gold Open Access)” basis will be entitled to a 50% discount on the “Open Access Plus (Gold Open Access)” publication fee.

For more information please contact us at e-mail: [email protected]

Bentham Science offers a 50% discount off the Open Access Plus (Gold Open Access) Fee for manuscripts of all corresponding authors who reside in countries which are categorized as low-income economies by the World Bank. To see if you qualify to the discount, please refer to the complete list of these countries click here .

Printed reprints and e-prints may be ordered from the Publisher prior to publication of the article. First named authors may also order a personal online subscription of the journal at 50% off the normal subscription rate by contacting the subscription department at e-mail: [email protected] .

Extend the scope and visibility of your research by creating an animated abstract. Bentham Science has collaborated with Focus Medica, one of the world’s largest publishers of expert animated atlases and videos in medicine and science.

An animated abstract will help summarise the essential discoveries/ key findings of your published research or review article. Each professionally produced full-coloured animated abstract in video format (length 3 – 5 minutes) is accompanied by an English spoken or foreign language commentary. The animated abstract will be published online along with the published article.

The payment for an animated abstract will be US $1320 . Initially, an advance amount of US $800 will be payable to the Publisher to start work on the Animated Abstract, while the balance of US $520 will be payable on completion of the Animated Abstract.

Authors who opt for the “Animated Abstract” option and also wish to have their article made available on an “Open Access Plus (Gold Open Access)” basis will be entitled to a 50% discount only on the Animated Abstract fee and, in addition, pay the normal Open Access Plus (Gold Open Access) fee.

Authors will be asked whether they wish to opt-in for this paid animated abstract service, and if not, the article will be published as normal. Animated abstracts are available as open access (free viewing) for maximum visibility and awareness to readers at anytime, anywhere. The animated abstracts are licensed under the terms of the Creative Commons Attribution – NonCommercial-NoDerivatives 4.0 International Public License (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/

For a sample of an animated abstract please access here https://www.benthamscience.com/pages/animated-abstract-video

Bentham Science offers discounts to those corresponding authors who are based in low-income countries*.

The authors who wish to avail this offer should request for a discount at the time of submission of their manuscripts to Bentham Science.

Bentham Science offers 50% discount on the Open Access Plus (Gold Open Access) Fee, Quick Track Fee and Article Processing Charges (APC) for manuscripts of the corresponding authors based in countries categorized as low-income economies by World Bank (list given below).

For any query or suggestion, please contact us on [email protected].

• Afghanistan
• Central African Republic
• Congo, Rep.
• Guinea-Bissau
• Marshall Islands
• Sierra Leone
• Yemen, Rep.
• Côte d'Ivoire

All papers submitted to Bentham Science for publication are immediately subjected to preliminary editorial scrutiny by the Editorial Staff and Editor-in-Chief in connection with their suitability. The Editor-in-Chief determines if the manuscript:

(a) falls within the scope of the journal and

(b) meets the editorial criteria of Bentham Science Publishers in terms of originality and quality.

Manuscripts that appear to be suitable are then subjected to double-blind peer review by, usually two to three, neutral eminent experts. The services of eminent international experts are sought through invitations to conduct the peer review of a submitted manuscript, keeping in view the scope of the manuscript and the expertise of the reviewers. The identities of both the reviewer and author are kept undisclosed to each other, ensuring anonymity and maintaining confidentiality throughout the entire review procedure. The anonymity of reviewers ensures an objective and unbiased assessment of the manuscript by the reviewers.

Before sending the manuscripts to reviewers, Bentham Science seeks consent from potential reviewers about their availability and willingness to review. Correspondence between the editorial office of the journal and the reviewers is kept confidential. The reviewers are expected to provide their reports in a timely fashion since a prompt review leads to the timely publication of a manuscript which is beneficial not only to the authors but to the scientific community as well.

The editorial process and peer-review workflow for each journal are taken care of by a team of Senior Editors, Editorial Board Members (EBMs) and dedicated Journal managers who have the required expertise in their specific fields.

Bentham Science Publishers carries out independent reviews of all articles. The reviewers are selected according to their expertise, from our, regularly updated, referee database.

On the basis of reviewer comments, the Editors may recommend acceptance, revision or rejection of a manuscript.

After a review of the manuscript by at least two or three independent experts, in addition to the views of the Editor, the decision is relayed to the authors, which may be categorized as:

Requires minor changes

Requires major changes

Rejected with no resubmission

If an article receives two contradictory reports, the Editor-in-Chief retains the right to request additional comments and the discretion to make the final decision without waiting for additional reports, taking into consideration the content and conclusions presented in all reports. This proactive approach ensures promptness in conveying the Editor's decision, thereby facilitating swift communication with the author.

Bentham Science requests not to have the manuscripts peer-reviewed by those experts who may have competing interest with the author(s) of a submitted manuscript. It is not possible for Editors to be aware of all competing interests; it is therefore expected that the reviewers would inform the Editor-in-Chief/Handling Editor if they notice any potential competing interest during the course of review of a manuscript. Moreover, the reviewers are expected to inform the Editors or editorial office of the journal if they have a conflict of interest in carrying out the review of a manuscript submitted by any author/contributor of the manuscript.

The authors are usually requested to resubmit the revised paper within 15 days and it will then be returned to the reviewers for further evaluation. The publishers normally allow one round of revision and, in exceptional cases, a second round of revision may be allowed. If further revision is needed, then the manuscript is rejected and the author is requested to resubmit the manuscript for fresh processing.

The final decision regarding acceptance or rejection is that of the Editor-in-Chief, depending on the quality of the revision and his assessment of the quality of the manuscript. In rare cases, manuscripts recommended for publication by the referees may be rejected in the final assessment by the Editor-in-Chief.

The time frame for revision of any article may vary from one to four weeks, depending on the nature of the revision required (minor or major). However, authors who need extra time for revision should consult the Editor-in-Chief/Handling Editor with valid reasons and the submission date of the revised manuscript may be extended if the request is genuine.

After the successful completion of the review and acceptance of the article, the articles are typeset and proofs are dispatched to authors for any corrections prior to final publication.

Plagiarism means copying or paraphrasing another writer's content, be it a text, a result or an observation, and stating it as one's own, without citing a reference to the original source. Therefore, authors should acknowledge and cite references to the work of other scientists in their manuscripts. The author should ensure that all the sources are authentic and that there is no discrepancy in the content of the manuscript.

Bentham Science is vigilant in checking and identifying the primary sources of the data within the content by using the iThenticate software to detect instances of overlapping and similarity of text in submitted manuscripts. iThenticate software verifies the content against a database of periodicals, materials on the Internet, and a comprehensive article database. The software generates a similarity report in percentage that matches the article in process and the published material. This similarity is further scrutinized for suspected plagiarism according to the publisher's Editorial Policies. The generated report comprises the overall percentage of the content reused.

The study of an author has to be original. If there are credible sources of the content referred to in the manuscript, the author needs to cite all of them. Authors are advised to use iThenticate before submitting a manuscript to ensure that there are no instances of plagiarism. Authors are required to provide proper consent from the individuals and contributions of other authors should be acknowledged.

Bentham Science has different editorial policies for authors who have more than one publication. Following those policies, the authors need to specify the sources of the submission in their recent work. For further details, please visit the following link of Editorial Policies for Concurrent Publication/Simultaneous Submission at https://benthamscience.com/pages/editorial-policies-main

Bentham Science strictly follows COPE guidelines to detect plagiarism. For clearer insight, authors may refer to the flowcharts provided by COPE by clicking here or visiting the COPE website.

To ensure the scholarly integrity of every article, Bentham Science will publish post-publication notices. The authors of the published articles, or those who have submitted the manuscripts with false information, or fabricated the supporting data or images, will be liable for sanctions, and their papers will be retracted. For further details, please visit complete guidelines at: https://www.benthamscience.net/fabricating-stating-false-information

Bentham Science is a publishing partner of Kudos. All authors who publish in this journal will receive an invitation to join the Kudos platform, an entirely free service for authors. Kudos enables authors to help broaden their audience and readers, increase their professional profile and reputation, and establish an impact for their publications. The website link is www.growkudos.com .

Kudos provides a free platform to researchers to have their publications accessible, read and cited across multiple networks and channels available to researchers for the dissemination of their work. It takes on average 15 minutes and leads to 23% higher growth in full-text downloads.

Authors are encouraged to explain their work in clear English and to attract researchers of the relevant communities, share a trackable link that you can email to your existing network of contacts, or share on social media and academic websites, and track how well the articles are performing through the summary of views, downloads, citations, and altmetrics on the Kudos dashboard.

Authors may also use the new shareable PDF (S-PDF) service. The S-PDF provides researchers with the means to write and share a high-level overview for each of their publications. Kudos thereby provides researchers, and their publishers and institutions, with a rich understanding of which channels and activities are most effective for broadening the reach and impact of published science.

Committee on Publication Ethics (COPE) is an advisory body that ensures the highest standards of editorial practice in scholarly publishing, by providing guidance to editors and publishers in all aspects of publication ethics.

Anti-Cancer Agents in Medicinal Chemistry is committed to upholding ethical standards in scholarly publishing. This journal is affiliated with COPE and adheres to its guidelines. To learn more about COPE guidelines, visit COPE website .

Bentham Science Publishers is pleased to offer electronic publication of accepted papers prior to scheduled publication. These peer-reviewed papers can be cited using the date of access and the unique DOI number. Any final changes in manuscripts will be made at the time of print publication and will be reflected in the final electronic version of the issue. Articles ahead of schedule may be ordered by pay-per-view from the relevant links given by each article stated via the E-Pub Ahead of Schedule

Articles appearing in E-Pub Ahead-of-Schedule sections have been peer-reviewed and accepted for publication in this journal and posted online before scheduled publication. Articles appearing here may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Accordingly, E-Pub Ahead-of-Schedule the editors, authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained in articles of the E-Pub Ahead-of-Schedule.

Generally, the editorial decisions are not reverted. However, authors who think that their manuscript was rejected due to a misunderstanding or mistake may seek an explanation for the decision. Appeals must give sound reasoning and compelling evidence against the criticism raised in the rejection letter. A difference of opinion as to the interest, novelty, or suitability of the manuscript for the journal will not be considered as an appeal. The EIC and other relevant editors will consider the appeal and the decision thereafter taken by the journal will be deemed final. Acceptance of the manuscript is not guaranteed even if the journal agrees to reconsider the manuscript, and the reconsideration process may involve previous or new reviewers or editors and substantive revision.

Authors who wish to make a complaint should refer them to the Editor-in-Chief of the journal concerned. Complaints to the Publisher may be emailed to [email protected]

• About Journal
• Editorial Board
• Journal Insight
• Current Issue
• Volumes /Issues
• Author Guidelines
• Graphical Abstracts
• Fabricating and Stating False Information
• Research Misconduct
• Post Publication Discussions and Corrections
• Publishing Ethics and Rectitude
• Increase Visibility of Your Article
• Archiving Policies
• Peer Review Workflow
• Order Your Article Before Print
• Promote Your Article
• Manuscript Transfer Facility
• Editorial Policies
• Allegations from Whistleblowers
• Forthcoming Thematic Issues
• Guest Editor Guidelines
• Editorial Management
• Ethical Guidelines for New Editors
• Reviewer Guidelines
• Abstract Ahead of Print 8
• Article(s) in Press 6
• Free Online Copy
• Most Cited Articles
• Most Accessed Articles
• Highlighted Article
• Most Popular Articles
• Editor's Choice
• Thematic Issues
• Open Access Articles
• Open Access Funding
• Library Recommendation
• Trial Requests
• Advertise With Us
• Meet the Executive Guest Editor(s)
• Brand Ambassador
• Author's Comment & Reviews
• New Journals 2023
• New Journals 2024
• Alert Subscription

Biography of

• Aims and Scope
• About the Journal
• Editorial Board
• Open Access

Article Processing Charge

• Accepted Articles
• Epub Ahead-of Print Articles
• Current Issue
• Most Read Articles
• Most Cited Articles
• Instructions for Authors
• Research and Publication Ethics
• E-submission
• Copyright transfer agreement

Article charges are required for publication in the Cancer Research and Treatment . These cover some of the costs of publication as well as open access online editions in the journal website ( http://www.e-crt.org ) or in the PubMed Central ( http://www.ncbi.nlm.nih.gov/pmc/journals/915/ ). Invoice will be sent to the corresponding author when the submitted article is finally accepted. The charge is USD 600 per article, and USD 300 for case report, correspondence or erratum.

Copyright © Korean Cancer Association. View Full Site

• Advanced search

Advanced Search

Visit the official website of the International Institute of Anticancer Research .

Current Issue

Issue highlights

• Combination Treatment of Biochanin A and Atorvastatin Alters Mitochondrial Bioenergetics, Modulating Cell Metabolism and Inducing Cell Cycle Arrest in Pancreatic Cancer Cells
• PIK3CA Hotspot Mutations in Saliva as a Diagnostic Marker in Oral Squamous Cell Carcinoma Patients
• High Level Immunoglobulin Gene Expression and Reduced Intra-tumoral Bacteria Associated With the Transition from Initial to Progressive Diffuse Intrinsic Pontine Glioma
• Photoimmunotherapy of Prostate Cancer With Antibody and Fab Fragments Targeting the Prostate Specific Membrane Antigen
• ARHGAP4 as a Prognostic Biomarker for Colon Liver Metastases After Surgical Resection

Our special issue of ANTICANCER RESEARCH on New Anticancer Agents - 2024​   is now online!

Click  here   to see the contents

Featured Articles

• Patient-derived Orthotopic Xenograft (PDOX) Nude Mouse Model of Soft-tissue Sarcoma More Closely... February 09, 2015
• Long Noncoding RNA ANRIL Regulates Proliferation of Non-small Cell Lung Cancer and... September 25, 2015
• The Effect of Various Doses of Oral Vitamin D 3 Supplementation on Gut Microbiota in... December 31, 2019
• Combination Immunotherapy with 4-1BB Activation and PD-1 Blockade Enhances Antitumor Efficacy in a... December 30, 2014
• Curcumin and Epigallocatechin Gallate Inhibit the Cancer Stem Cell Phenotype via Down-... December 30, 2014
• A Long Noncoding RNA, lncRNA-ATB, Is Involved in the Progression and Prognosis of Colorectal Cancer March 06, 2015

Latest Articles

• You have access A Comparative Analysis of ARX and ANFIS Models for Tumor Growth Prediction Under Single and Multi-agent Chemotherapy SOTIRIOS G. LILIOPOULOS , GEORGE S. STAVRAKAKIS and KONSTANTINOS S. DIMAS Anticancer Research June 2024, 44 (6) 2425-2436; DOI: https://doi.org/10.21873/anticanres.17049
• You have access DNA Hypermethylation Inhibits the CD82 Metastasis Suppressor Gene in Gastric Cancer JI-WOONG PARK , WOONG KIM , HYEON-GU KANG , WON-JIN KIM , HANA LEE , DABIN CHOI and SEOK-JUN KIM Anticancer Research June 2024, 44 (6) 2459-2470; DOI: https://doi.org/10.21873/anticanres.17053
• You have access Comprehensive Analysis of Blood Test Results Predicting Prognosis in Patients Undergoing Whole-brain Radiotherapy for Brain Metastases CARSTEN NIEDER , LUKA STANISAVLJEVIC and BÅRD MÅNNSAKER Anticancer Research June 2024, 44 (6) 2637-2643; DOI: https://doi.org/10.21873/anticanres.17070
• Open Access DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal Fibroblasts SEI MORINAGA , QINGHONG HAN , YUTARO KUBOTA , KOHEI MIZUTA , BYUNG MO KANG , MOTOKAZU SATO , MICHAEL BOUVET , NORIO YAMAMOTO , KATSUHIRO HAYASHI , HIROAKI KIMURA , SHINJI MIWA , KENTARO IGARASHI , TAKASHI HIGUCHI , HIROYUKI TSUCHIYA , SATORU DEMURA and ROBERT M. HOFFMAN Anticancer Research June 2024, 44 (6) 2359-2367; DOI: https://doi.org/10.21873/anticanres.17043
• You have access Association Between Preoperative Osteopenia and Prognosis in Breast Cancer Patients SACHIE OMORI , HIDEKI IJICHI , AYAKO WAKASUGI , TOMOKO SHIGECHI , EIJI OKI , MAKOTO KUBO and TOMOHARU YOSHIZUMI Anticancer Research June 2024, 44 (6) 2671-2679; DOI: https://doi.org/10.21873/anticanres.17074
• Open Access Identification of BRAF Inhibitor Resistance–associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening XUAN WEN , MIN HAN , MASAKI HOSOYA , RIKA TOSHIMA , MAI ONISHI , TOMOAKI FUJII , SHIGEO YAMAGUCHI and SHUNSUKE KATO Anticancer Research June 2024, 44 (6) 2349-2358; DOI: https://doi.org/10.21873/anticanres.17042

About the Journal

Focus and scope.

Proceedings of Anticancer Research (PAR) is an international peer-reviewed and open access journal, which is devoted to the rapid publication of high-quality original articles, reviews, case reports, short communication and letters on all aspects of experimental and clinical oncology. The covered topics include, but are not limited to: cellular research and bio-markers, identification of bio-targets and agents with novel mechanisms of action, preventative and integrated treatments for cancer patients, radiation and surgery, palliative care, patient adherence, quality of life, satisfaction, and anticancer medicine.

Peer Review Process

All the manuscripts submitted to the Proceedings of Anticancer Research (PAR)  will need to go through the following procedure:

• The manuscripts will be pre-screened by the in-house editors to ensure adherence to the journal policies.
• If a manuscript is deemed suitable for publication in the journal, the Editorial Office will proceed to arrange the manuscript for peer review. The reviewers will be selected from the Editorial Board or other external scholars or researchers. A double-blind peer review procedure is applied to all manuscripts of relevant article types.
• A review report including the Editorial Decision (Accept, Minor Revision, Major Revision or Reject) made on the advice of the Editor-in-Chief will be prepared and sent to the authors following the peer review process.
• The author is required to address the comments and inquiries in the review report if the Editorial Decision is Minor Revision or Major Revision. In general, the authors should revise and resubmit the paper within 7 days and 14 days upon receipt of the review report if the Editorial Decision is Minor Revision and Major Revision, respectively.
• Same procedure is applied to the revised paper.

Authors may appeal for a rejected submission. All appeal requests must be made in writing to [email protected] with detailed reasons for the appeal, and point by point responses to the review comments. Decisions on the appeals are final.

The peer-review process is completed once the paper is accepted for publication. The paper will then be arranged for article production which encompasses copy-editing, typesetting and proofreading prior to online publication.

Note: The authors may suggest up to four reviewers from the academic background. The field of the subject matter as described in the submission should match with the research field of the suggested reviewers. The list of the suggested reviewers and their details such as full name, affiliation, email address, etc. should be included in the cover letter which should be submitted during the manuscript submission stage. However, whether or not the suggested reviewers should be recruited to review the manuscript is at the editorial office’s discretion, and the editorial office has the authority to select new reviewers.

Open Access Policy

Proceedings of Anticancer Research (PAR) provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Publishing Ethics

Proceedings of Anticancer Research (PAR) requests all members involved in the journal publishing process to adhere to the Core Practices on publication ethics as stipulated by  Committee on Publication Ethics (COPE)  in compliance with the information and guidelines on handling publishing ethics allegations as described in the  Publishing Ethics Resource Kit (PERK) .

The journal editors take all possible misconduct seriously. The Editors, authors or readers can forward their concerns to the journal if they find out that the description in a submitted article may constitute an academic fraud, research misconduct or publication malpractice. The concerns or complaints on the possible allegations submitted to the journal will be dealt with promptly and appropriately according to the procedure set out in the COPE flowchart on complaints and in PERK. The complainant may direct all inquiries and correspondence to the Publisher at [email protected].

Editorial Policies

Authors should read the  Author Guidelines  before making a submission, and make sure that the manuscripts were written in accordance to the style and specifications of the journal’s policy.

All manuscripts submitted to Proceedings of Anticancer Research (PAR)  are subject to rigorous peer review. Prior to peer review process, the manuscripts will be screened for acceptable English language, novelty and relevance to the Focus and Scope of the journal.

Any manuscripts submitted to Proceedings of Anticancer Research (PAR)  will be treated as confidential materials. The manuscripts will not be disclosed to anyone except individuals such as editorial staff, reviewers and editors who participate in the initial screening, peer review, processing and preparation of the manuscript for publication (if accepted).

Acknowledgments

The Acknowledgments section in a paper serves to indicate the individuals, agencies and/or institutions whose contributions merit acknowledgment, rather than authorship. The roles that merit acknowledgment include the acquisition of funding, general supervision of a research group or general administrative support, writing assistance such as technical editing and language editing, as well as proofreading.

The authors should also acknowledge technical assistance involved in the experiments and field trips, as well as assistance in non-technical form such as intellectual discussions.

The authors are also required to declare what financial support they obtained to perform their research. Thus, the authors should acknowledge the funders and mention the roles of the funders in the research as well as the research grant information, e.g. the grant number, in this section. 

Conflict of Interest

The authors are required to provide the authorization of no conflict with any financial body or funding agency that might influence the results or interpretation of their manuscripts. All authors, members, reviewers and editors must disclose any association that poses a conflict of interest in connection with the manuscript.

A manuscript would not be accepted if it has been published or is currently under consideration for publication in any other journals. The authors are required to notify the editorial team if the findings and data in their submissions have been presented in conferences.

Author Proofreading

The Editorial Office will send a galley proof to the authors for proofreading at least one week after a manuscript has been accepted. The authors are responsible to read and check the entire proof, and inform the Editorial Office if some mistakes need to be corrected. In general, only minor mistakes will appear in the galley proof, such as typographical errors, layout issue, etc. Significant changes that can affect the scientific integrity and interpretation of findings in the accepted manuscript can be made during the proofreading stage.

Corrections and Additions to Published Papers

The authors are not allowed to make corrections, including addition and deletion of contents in papers after they have already been published.

A corrigendum or an addendum is published at the sole discretion of the editors.

Advertising Policy

All advertisements are subject to approval by the Bio-Byword Scientific Publishing. The advertisements must comply with the relevant regulations in the country where the advertisements appear. Contact the Editorial Office ([email protected]) for more information.

Data Processing Policy

The authors are required to clearly state in the figure legend and in the Methodology section or its equivalent, if alterations (e.g. brightness, contrast, color balance) have been applied to the images.

The Editorial Office reserves the right to request the original data, e.g. raw data and images, from the authors if inappropriate manipulation of data is suspected after paper publication. The suspected paper will be retracted in accordance with the standard guidelines if the claim of data manipulation is proven to be true.

Article Processing Charge

The authors are required to pay the Article Processing Charge (APC) for publishing with Proceedings of Anticancer Research (PAR) to cover the cost incurred in processing the manuscripts in order to ensure the contents are freely available and to maintain publishing quality. The manuscript processing includes peer review, copy-editing, typesetting, publishing, content depositing and archiving processes. An invoice of APC will be issued after a paper has been accepted, where authors are advised to pay the APC within one week to avoid delay in publication.

The APC for processing each article is AUD 600. 

Copyright and License

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License  

Proceedings of Anticancer Research publishes accepted manuscripts under  Creative Commons Attribution 4.0 International License (CC BY 4.0) . Authors who submit their papers for publication in  CAS Medicine  agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part thereof free of charge for any purpose, including commercial use. As long as the author and original source is properly cited, anyone may copy, redistribute, reuse and transform the content. 

Reuse of article content

Anyone is free to reuse  Proceedings of Anticancer Research article content licensed under CC BY 4.0 provided that proper attribution is given through citation of the original source.

• Google Scholar
• National Library of Australia
• Peking University Library
• Baidu Xueshu
• For Readers
• For Authors
• For Librarians
• AACMAC Australian Acupuncture & Chinese Medicine Annual Conference 2024 - 2~4 August 2024, Brisbane
• ACM Conference on International Computing Education Research (ICER) 2024 - 13~15 August 2024, Melbourne
• International Dementia Conference 2024 - 5~6 September 2024, Sydney
• 45th ICMM World Congress on Military Medicine 2024 - 22~27 September 2024, Brisbane
• 3rd World Congress on Alcohol and Addictions 2024 - 23~26 September 2024, Melbourne
• 17th Asia Pacific Heart Rhythm Society Scientific Sessions 2024 - 26~29 September 2024, Sydney
• UbiComp'24: The 2024 ACM International Joint Conference on Pervasive and Ubiquitous Computing - 5~9 October 2024, Melbourne
• International Menopause Society: 19th World Congress on Menopause – 19~22 October 2024, Melbourne
• MM’24: The 32nd ACM International Conference on Multimedia – 28 October~1 November 2024, Melbourne
• 2025 9th International Conference on Sustainable Energy Engineering (ICSEE 2025) - 18~20 January 2025, Melbourne
• 10th World Archaeological Congress 2025 – 22~27 June 2025, Darwin
• The World Green Infrastructure Congress 2024 - 3~5 September 2024, Auckland

Article Processing Charges

Journal Title
	$1390*
* Editorial, editorial commentary and review articles that are commissioned by Editorial Office are free of charge.

What does the Article Processing Charge include?

• Developing and maintaining electronic tools for peer review and publication
• Article production and preparation in various formats for publication
• Immediate, worldwide open access to the full article text
• Liaison with abstracting and indexing services

Updated on April 21, 2023

Article processing charges

All articles published in our journals are open access and freely available online, immediately upon publication. This is made possible by an article-processing charge (APC) that covers the range of publishing services we provide. This includes provision of online tools for editors and authors, article production and hosting, liaison with abstracting and indexing services, and customer services. The APC, payable when your manuscript is editorially accepted and before publication, is charged to either you, or your funder, institution or employer.

Frequently-asked questions (FAQ)

Who is responsible for making or arranging the payment.

As the corresponding author of the manuscript you are responsible for making or arranging the payment (for instance, via your institution) upon editorial acceptance of the manuscript.

At which stage is the amount I will need to pay fixed?

The APC payable for an article will be determined from the date on which the article is accepted for publication.

When and how do I pay?

Upon editorial acceptance of an article, the corresponding author (you) will be notified that payment is due. You need to arrange payment unless a waiver has been granted, or your institution or employer is covering the cost through our Membership Program .

We advise prompt payment as we are unable to publish accepted articles until payment has been received.

Payment can be made by any of the following methods:

• Credit card - payment can be made online using a secure payment form as soon as the manuscript has been editorially accepted. We will we send a receipt by email once payment has been processed.
• Invoice - payment is due within 30 days of the manuscript receiving editorial acceptance. Receipts are available on request. Please note that payment other than by credit card carries an administrative surcharge of £50.  

No taxes are included in this charge. If you are resident in any European Union country you have to add Value-Added Tax (VAT) at the rate applicable in the respective country.  Institutions that are not based in the UK and are paying your fee on your behalf can have the VAT charge recorded under the EU reverse charge method, this means VAT does not need to be added to the invoice. Such institutions are required to supply us with their VAT registration number. If you are resident in Japan you have to add Japanese Consumption Tax (JCT) at the rate set by the Japanese government.

Can charges be waived if I lack funds?

Springer Nature will consider requests from authors in financial need on a case-by-case basis. For more information, please see our open access policies for journals .

Will I have to pay if my institution is a Member?

Over 500 institutions worldwide have joined our Membership Program and financially support open access by paying some or all of the APCs on behalf of their researchers. Check if your institution is a Member. If it is, you will have the option of highlighting this after editorial acceptance.

I am from a low-income country, do I have to pay an APC?

Springer Nature offers APC waivers to papers whose corresponding authors are based in countries classified by the World Bank as low-income economies. For more information, please see our publication policies .

What funding sources are available?

Many funding agencies allow the use of grants to cover APCs. An increasing number of funders and agencies strongly encourage open access publication. For more detailed information and to learn about our support service for authors, see our OA funding and policy support page .

APC waivers for substantial critiques of articles published in OA journals

Where authors are submitting a manuscript that represents a substantial critique of an article previously published in the same fully open access journal, they may apply for a waiver of the article processing charge (APC).

In order to apply for an APC waiver on these grounds, please contact the journal editorial team at the point of submission. Requests will not be considered until a manuscript has been submitted, and will be awarded at the discretion of the editor.  Contact details for the journal editorial offices may be found on the journal website.

What is your APC refund policy?

Springer Nature will refund an article processing charge (APC) if an error on our part has resulted in a failure to publish an article under the open access terms selected by the authors. This may include the failure to make an article openly available on the journal platform, or publication of an article under a different Creative Commons licence from that selected by the author(s). A refund will only be offered if these errors have not been corrected within 30 days of publication.

If you become aware of an error in the open access status or licensing of your article, please contact the Global Open Research Support Team immediately ([email protected]).

APCs will not be refunded when articles are retracted as a result of author error or misconduct.

International Institute of Anticancer Research

Founded in 1995.

• Anticancer Research
• Cancer Genomics & Proteomics
• Cancer Diagnosis & Prognosis
• Conferences

Reprints, Open Access (OA), PDF

Please address requests for reprints, OA, PDF to the Editorial Office (e-mail: [email protected] ) with any specific requirement (color covers, shrink wrapping, addition of codes, etc)..

	450	550	650	750	850
	150	150	150	150	150
	210	230	250	270	290
	270	300	330	360	390
	340	380	420	460	500
	410	450	490	530	570
	480	520	560	600	640
	550	590	630	670	710
	850	950	1,050	1,150	1,250
	1,250	1,360	1,470	1,580	1,690
	1,650	1,770	1,890	2,010	2,130
	2,050	2,200	2,350	2,500	2,650

For reprints with cover: Please add US $ 70.00 per 100 copies. Postage: Please add 5% on the reprints’ prices. The reprints are not to be sold.

To obtain permission to reuse or reproduce our content, ANTICANCER RESEARCH has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit www.copyright.com and enter the title that you are requesting permission for in the ‘Get Permission’ search box.

IMPORTANT NOTE: You may submit your article only through our online submission system

Submit your manuscript, privacy overview.

Cookie	Duration	Description
_ga		Used by Google Analytics
_ga_KS62C0E414		Used by Google Analytics
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Information

• Author Services

Initiatives

You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .

Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.

Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.

Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.

Original Submission Date Received: .

• Active Journals
• Find a Journal
• Proceedings Series
• For Authors
• For Reviewers
• For Editors
• For Librarians
• For Publishers
• For Societies
• For Conference Organizers
• Open Access Policy
• Institutional Open Access Program
• Special Issues Guidelines
• Editorial Process
• Research and Publication Ethics
• Article Processing Charges
• Testimonials
• Preprints.org
• SciProfiles
• Encyclopedia

Journal Menu

• Cancers Home
• Aims & Scope
• Editorial Board
• Reviewer Board
• Topical Advisory Panel
• Instructions for Authors
• Special Issues
• Sections & Collections
• Article Processing Charge
• Indexing & Archiving
• Editor’s Choice Articles
• Most Cited & Viewed
• Journal Statistics
• Journal History
• Journal Awards
• Society Collaborations
• Conferences
• Editorial Office

Journal Browser

• arrow_forward_ios Forthcoming issue arrow_forward_ios Current issue
• Vol. 16 (2024)
• Vol. 15 (2023)
• Vol. 14 (2022)
• Vol. 13 (2021)
• Vol. 12 (2020)
• Vol. 11 (2019)
• Vol. 10 (2018)
• Vol. 9 (2017)
• Vol. 8 (2016)
• Vol. 7 (2015)
• Vol. 6 (2014)
• Vol. 5 (2013)
• Vol. 4 (2012)
• Vol. 3 (2011)
• Vol. 2 (2010)
• Vol. 1 (2009)

Find support for a specific problem in the support section of our website.

Please let us know what you think of our products and services.

Visit our dedicated information section to learn more about MDPI.

Advances in Anticancer Drugs and Pharmacotherapy of Cancer

• Print Special Issue Flyer

Special Issue Editors

Special issue information.

• Published Papers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section " Cancer Drug Development ".

Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 60118

Share This Special Issue

Dear Colleagues,

The pharmacotherapy of cancer has experienced some encouraging novel developments. A new armamentarium of anticancer drugs and their delivery have led to improvements not only in efficacy and safety profiles but also the quality of life both pre and post treatment.

The regulatory approval of several new targeted immunotherapies indicates their success in clinical trials for treating multiple types of cancer. Using a targeted immunotherapy approach, oncologists can firstly screen for protein or genetic abnormalities in a patient’s tumor and then match those with appropriate immunotherapies. Immunotherapy boosts the body’s immune system to attack cancer cells through applications of CAR T-cell therapy, immune checkpoint inhibitors, monoclonal antibodies, treatment vaccines, and immune system modulators.

In terms of drug delivery systems, the use of innovative chemotherapy delivery systems, such as pressurized intraperitoneal aerosol chemotherapy (PIPAC), has significantly reduced the severity of the side effects of systematically delivered chemotherapy. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique delivering normothermic chemotherapy into the abdominal cavity as an aerosol under pressure. Early stage trials involved administering intraperitoneal chemotherapy to multiple areas of metastasis in the abdominal area. The involved tumors normally consist of small nodules that have proliferated to such a widespread extent that they are challenging to treat using surgical incision. Likewise, conventional intravenous chemotherapy is inferior when compared with PIPAC, which applies the same standard technique used in diagnostic laparoscopy. Such direct delivery of anticancer drugs into the abdomen via a nebulizer pen, channeling an aerosolized form of chemotherapy deep into the abdominal crevices, ensures that residual drugs are subsequently removed.

This Special Issue of Cancers will cover theoretical and applied aspects of cancer drug discovery, formulation, product development, and clinical practices. Submissions presenting research related to chemical identification, in vitro/in vivo/in silico evaluation of anticancer agents, including natural products, or complementary medicine in original research and review articles are welcome.

Dr. Muhammad Abdul Hadi  Dr. Md. Sanower Hossain Dr. Bey-Hing Goh Guest Editors

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website . Once you are registered, click here to go to the submission form . Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

anticancer drugs

• hormone therapy
• immunotherapy
• complementary medicine
• dosage form design
• chemotherapy

Published Papers (21 papers)

Jump to: Review , Other

Graphical abstract

Jump to: Research , Other

Jump to: Research , Review

Further Information

Mdpi initiatives, follow mdpi.

Subscribe to receive issue release notifications and newsletters from MDPI journals

• Submit your Research
• My Submissions
• Article Guidelines
• Article Guidelines (New Versions)
• Data Guidelines
• Article Processing Charges
• Peer Review
• The Peer Review Process
• The Editorial Team’s Role
• Understanding Peer Review Reports and Statuses
• Revising and Responding to Reviewers
• Finding Article Reviewers
• Reviewer Criteria
• Hints and Tips for Finding Reviewers
• Dos and Don’ts for Suggesting Reviewers

Open Access Article Publishing Charges

Authors can publish one or more new versions of a published article. A revised version is usually published in response to points raised during the peer review process – revised versions are published at no extra charge; an update is a new version that reflects small developments in the research since publication – updates carry a charge of US $400 per update.

F1000Research Advisory Board members : Our advisory board receive a 20% discount.

F1000Research reviewers: All reviewers receive a 20% discount on one article submitted within the ensuing 12 months.

Discounts cannot be combined to cover the fee for a single article. If authors on an article are eligible for various individual discounts, the largest discount is applied.

Submitting authors with primary affiliation in countries defined by the World Bank as low-income economies are entitled to 100% APC waiver. A 50% discount on the normal APC is also available to authors from countries defined by the World Bank as lower-middle income economies, who have a 2021 gross domestic product (GDP) of less than 200 billion US dollars. Our waiver policy only applies to submitting authors.

• Afghanistan
• Burkina Faso
• Central African Republic
• Democratic Republic of the Congo
• Guinea-Bissau
• Sierra Leone
• South Sudan
• Syrian Arab Republic
• Republic of Yemen
• Republic of the Congo
• Côte d’Ivoire
• Kyrgyz Republic
• Federated States of Micronesia
• Papua New Guinea
• São Tomé and Principe
• Solomon Islands
• Timor-Leste

These agreements allow institutions to arrange direct payment of article processing charges and reduce the associated administrative burden. Institutions can also foster and raise the profile of their Open Access research through personalized Institutional Collections of related research outputs. For more information, please contact us .

F1000Research is committed to providing transparency where possible to demonstrate the services and value we provide for authors. The following APC breakdowns for all F1000Research price categories use the Information Power’s Plan S Price Transparency framework breakdown scheme .

F1000Research has a community outreach program working collaboratively with researchers to develop and manage gateways and collections , supporting those communities in publishing a wide range of academic outputs. F1000Research continues to innovate around editorial guidelines and policies , which incorporate Findable, Accessible, Interoperable, Reusable (FAIR) data principles and software availability to encourage the best open research practices. F1000Research is an actively contributing member of various industry organizations including COPE and OASPA , and works closely with organizations like Crossref , FAIRSharing and ORCID to move towards to a more interoperable and connected research infrastructure.

Articles submitted to F1000Research first undergo an editorial triaging process which assess article scope and eligibility, check for plagiarism, and assess whether the underlying data and software has been made available. Before, during and after these checks the F1000Research editorial team also respond to editorial enquiries and provide information to the authors on what is required in order for the full pre-publication checks to begin.

Our in-house editorial team provide a comprehensive service that consists of a set of rigorous pre-publication checks to ensure that all the editorial policies and reporting and ethical guidelines are adhered to. This service includes in-house data and software support where the team advise and guide authors how to ensure their data is FAIR and can be accessed from the information included in the data availability statement. Upon acceptance, the production team ensure articles are made available in industry standard formats (PDF, HTML, XML) so that all content is fully text and data minable. Before an article is published, the production team provide proofs and perform quality checks on citations and references, image resolutions, any included multimedia, as well as ensuring persistent identifiers are assigned and resolve correctly.

The editorial team identify and invite expert peer reviewers, and verify any reviewer suggestions made by authors. When a review is submitted, the editorial team check the review and its accompanying peer review status and publish the reviews and names of the reviewers alongside the article. All peer review enquiries and peer review support (including helping find suitable reviewers) are managed by our in-house editorial team.

Once an article is published, F1000Research provides authors with detailed article-level metrics to see and measure the impact of their work. F1000Research ensures articles are discoverable by including content in major bibliographic indexers (e.g. PubMed, PubMed Central, MEDLINE, Europe PMC, Scopus etc.) and ensuring the content is preserved in perpetuity by archiving it through Portico. For readers, all articles can be live-tracked and easily found through customisable article alerts and feeds.

F1000Research has a scalable, custom-built publishing infrastructure supporting the open research publishing process including registration, submission, publication, post-publication peer review and article versioning. In addition to publishing technology, F1000Research has a built-in peer reviewer selector tool, technology to safeguard quality control, and an agile central management system to support our gateway communities. F1000Research regularly innovates to make content more dynamic, interactive and reproducible , pioneering many firsts such as living and interactive figures and continuous publishing. F1000Research also develops technology that integrates, syndicates and is interoperable with important systems that support the wider research life cycle.

F1000Research’s marketing and communications team use social media, digital media, monthly newsletters and blogs to promote and highlight authors work. The Marketing and Communications team support our publishing community with promotional material for editorial campaigns, partner sponsorships and academic conference and events. More broadly, they also support the promotion and communication of F1000Research’s open research mission. F1000Research also works closely with institutions, societies and other academic institutions on open access publishing agreements to minimise the administrative effort required by authors and institutions in finding funds to cover publishing costs.

F1000Research regularly surveys authors and has a dedicated editorial service helpdesk where authors, reviewers and readers can send enquiries and/or feedback on their publishing experience. F1000Research welcomes open debate and discussion and supports and manages an open and transparent commenting functionality for registered users.

Keep up to date with the NC3Rs

Please enter your details to receive updates from the NC3Rs

We'll update you about the NC3Rs and the NC3Rs Gateway.

The email address should be the one you originally registered with F1000.

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here .

If you still need help with your Google account password, please click here .

You registered with F1000 via Facebook, so we cannot reset your password.

If you still need help with your Facebook account password, please click here .

If your email address is registered with us, we will email you instructions to reset your password.

If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.